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ABSTRACT 
Increasing global migration influences the epidemiology of infectious 
diseases. Migrants are over-represented among cases of hepatitis B and C, 
HIV and syphilis in many European countries, including Finland. However, 
there is only limited evidence of the infection prevalence and risk factors 
among migrant populations as well as on the effectiveness of approaches for 
prevention and early diagnosis. 
The aim of this study was to describe the burden of hepatitis B and C, HIV 
and syphilis among migrants in Finland, and to evaluate opportunities for 
public health response. The study objectives were to describe the feasibility 
of screening in a migrant population-based survey context, to estimate the 
seroprevalence of infections, to evaluate the implementation of screening, 
and to assess HIV-related health literacy among specific migrant 
populations. 
The data were collected from three surveys and from two national 
registers. The Migrant Health and Wellbeing Survey (Maamu) invited 
randomly selected adult migrants of Kurdish, Russian and Somali-origin to 
undergo screening for hepatitis B and C, HIV and syphilis. The survey sample 
was linked to the national infectious disease register to assess non-
participation and previous notifications. The coverage and timing of hepatitis 
B, HIV and syphilis screening among all asylum seekers in Finland in 2015–
2016 was assessed based on register information of healthcare procurements. 
HIV-related knowledge, attitudes and practices were compared between a 
convenience sample of 20 to 25-year-old asylum seekers originating from 
Africa, Middle East and the former Soviet Union, and a random sample of 
age-matched general population in Finland. 
Provider-initiated multiphasic screening of hepatitis B and C, HIV and 
syphilis proved feasible in a migrant population-based health survey context. 
Notification prevalence of hepatitis B or C, HIV or syphilis did not differ 
among participants and non-participants of the survey. Acceptability of HIV 
testing was increased by enhanced pre-test counselling. 
Hepatitis B and C, HIV and syphilis seroprevalence rates among the 
Kurdish, Russian and Somali-origin migrants and asylum seekers were in 
general comparable to or lower than in their countries of origin, but higher 
than among the general population in Finland. In the Maamu survey, 
seroprevalence of hepatitis B surface antigen (HBsAg) was 2.3%, hepatitis C 
antibodies (HCVAb) 1.7%, and Treponema-specific antibodies (TrpaAb) 1.3% 
among adult Kurdish, Russian and Somali-origin migrants. No cases of HIV 
were identified. The burden of hepatitis B was highest among Somali-origin 
migrants and that of hepatitis C and syphilis among Russian migrants. 
Among asylum seekers, HBsAg seroprevalence was 1.4%, HIVAgAb 0.3%, 
  
and TrpaAb 1.0%. HCVAb and TrpaAb seroprevalences increased with age 
both among resident migrant and asylum seekers. 
The coverage of after-arrival infectious disease screening was 87.5% 
among screening-eligible Kurdish, Russian and Somali migrants, and 60.6% 
among asylum seekers in Finland in 2015–2016. Previous HIV testing was 
reported by 31.4% of the Maamu participants and was associated with female 
gender. Previous HIV testing was reported by 23.4% of the young adult 
asylum seekers and 18.0% of the young adult general population. 
Of all test-positive cases in Maamu, 60.7% had no previous notification in 
the national infectious disease register and were considered as missed 
diagnoses. The burden of missed hepatitis C and syphilis was high among 
Russians, the largest migrant population in Finland. The majority of 
Russian-origin migrants are not targeted by current screening 
recommendations for asylum seekers and refugees. Missed hepatitis B 
diagnoses among the Somali-origin migrants suggest hepatitis B infections 
post-migration. The average delay from arrival to screening was 47 days for 
asylum-seeking children and 91 days for adult asylum seekers in 2015–2016. 
HIV-related knowledge was below the international target level among 
young adult asylum seekers. Asylum seekers preferred passive sources of HIV 
information to interpersonal strategies of health education. 
In conclusion, although asylum and integration processes are windows of 
opportunity for health education, prevention and screening, barriers 
hindering their implementation exist. Findings from this study suggest 
opportunities for further research and public health response addressing 
vulnerabilities to hepatitis B and C, HIV and syphilis among migrants in 
Finland. These opportunities include extending after-arrival screening of 
hepatitis B, HIV and syphilis to target all at-risk migrants, inclusion of 
hepatitis C screening, describing and addressing barriers hindering 
implementation of screening, enhancing provider-initiated screening, 
investing in health literacy, and ensuring a continuum of care for all 
migrants. 
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1 INTRODUCTION 
Migration, urbanization, demographic change, global warming and digital 
and technical revolution are interlinked global megatrends that influence 
societies, economies, culture and health, including epidemiology of infectious 
diseases 1, 2. The number of international migrants is continuously increasing 
and migration has become a complex and multidirectional phenomenon 3. 
In many European countries, including Finland, migrants are 
overrepresented among cases of hepatitis B and C, HIV and syphilis 4, 5. To an 
extent the higher burden of infections among migrants can be explained by 
pre-migratory factors: epidemiology of infections in countries of origin and 
transit and poor healthcare coverage amongst other social determinants of 
migrant health. Poverty is a major driver of poor health including infections 
6-9. 
An increasing body of evidence suggests that migrants’ vulnerabilities to 
infection are not properly addressed in current countries of residence and 
there is on-going transmission post-migration. Public health policies 
disproportionately limit the access, affordability and availability of health 
services for migrants and preventive measures fail to reach those at risk 10, 11. 
Hepatitis B and C, HIV and syphilis are blood-borne and sexually 
transmitted infectious diseases characterized by relatively long asymptomatic 
phases of latency, severe sequala, and availability of treatment that can 
considerably decrease the infection-associated morbidity, mortality and 
prevent further transmissions. Hepatitis B infections can be prevented with 
vaccinations. Screening of asymptomatic individuals is the key for early 
diagnosis, treatment and prevention of hepatitis B and C, HIV and syphilis. 12 
Facing these global trends in population dynamics, public health systems 
need to adapt to the service needs of the diverse and multicultural 
population. This study describes the burden of hepatitis B and C, HIV and 
syphilis among selected migrant populations in Finland, and evaluates 
strategies for prevention and early diagnosis of infections. 
Review of the literature 
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2 REVIEW OF THE LITERATURE 
2.1 MIGRATION, HEALTH AND INFECTIOUS DISEASES 
2.1.1 DEFINITIONS 
The International Organization for Migration (IOM) defines a migrant as a 
“person who is moving or has moved across an international border or within 
a State from his/her habitual place of residence” 13. Long-term residency is 
the result of migration lasting at least one year, as opposed to tourism or 
other short-term mobility 14. Labour migrants are persons who migrate for 
the purpose of seeking employment 13. 
Asylum seekers are persons seeking for international protection in a 
foreign country and awaiting a decision on the application of refugee status 
13. Refugee status is established by governments based on the 1951 
Convention relating to the Status of Refugees and supported by United 
National Refugee Agency (UNHCR) if necessary 15, 16. UNCHR-recognized 
refugees needing most urgent help are selected in the annual refugee quota in 
Finland 17. Irregular migration refers to migration outside the regulatory 
norms of sending, transit and receiving countries 14. 
Categorical determinants for migrant origin include country of origin, 
country of birth, nationality, ethnicity, race and native language amongst 
others. Country of birth is the most commonly used indicator of migrant 
origin in Finland as well as other European Union (EU) countries. 18, 19 
Country of origin is defined by several population databases, including 
Statistics Finland, as the parents’ country of birth 20.  
Keeping in mind the complexity of migration trajectories, it is of note that 
country of birth might differ from country of origin, nationality and prior 
country of residence. Any single definition of a migrant rarely applies at an 
individual level 7.  The majority of European population databases do not 
record reasons for migration 18. Other definitions for domestic and circular 
migration have been adopted in the scientific literature 21, 22. This thesis will 
focus on first-generation international migrants defined as persons with 
foreign origin born abroad. 
2.1.2 TRENDS IN MIGRATION AND DISPLACEMENT 
Migration is a global megatrend that has multi-faceted impacts on 
individuals and societies. Migration patterns are increasingly complex and 
diverse, and are specific to location, time and population. Most countries in 
the world are both sending and receiving migrants. 3 
  
Migration is a circular process from country of birth to subsequent 
countries of residence and possible return 18. Migration circles take place at 
varying speed, repeatedly and are integrated within the lifecycle of an 
individual 1, 18, 21. Push and pull factors influence the decision to migrate and 
include economic, social, environmental, conflict-related and political 
dimensions 23. Migration decisions range from voluntary to forced migration 
1. 
The global number of international migrants has almost tripled since the 
1970s 3. Migrants represented 3.4% (258 million) of the world population in 
2017 and the majority of them resided in Asia (80 million) and Europe (78 
million) 24. Migration corridors differ between countries and regions, have 
developed through history and are shaped by economic factors, public 
policies, conflict, ethnic ties and trafficking 3. Globally, almost three quarters 
of migrants were adults of working age (20 to 64 years) 24. Labour migration 
is the major driver of global migration accounting for two-thirds of all 
international migrants 3.  
In 2017, 68.5 million persons were forcibly displaced and 26 million had 
fled across an international border, representing one-tenth of international 
migrants globally 25, 26. Children under 18 years of age represented 52% of the 
refugee population. The major source countries of refugees in 2017 were 
Syria, Afghanistan and South Sudan, and neighbouring countries Turkey, 
Pakistan and Uganda were the top receiving countries. 26 During 2015–2016, 
Europe faced a large influx of 2.6 million asylum seekers with Germany, Italy 
and Sweden receiving the largest number of applications 27, 28. The number of 
migrants in irregular situations in the EU in 2008 was estimated at 2–8 
million 3.  
The majority of international migrants move between countries of the 
same region, as in case of Europe where 67% of migrants (41 million) are 
born in other European countries. In Europe, 10.5% of the total population in 
2017 were migrants, of whom 52.0% were women. 24 Germany, the United 
Kingdom and Spain had the largest number of migrants in EU/EEA in 2016 
whereas Luxembourg, Malta and Cyprus had the largest migrant populations 
relative to number of inhabitants 29. 
In Finland, 5.8% (321,494) of the population in 2017 were international 
migrants. The largest migrant populations originated from Former Soviet 
Union (FSU) or Russia (71,601), Estonia (43,607), Iraq (16,306) and Somalia 
(12,121). Males were 51.3% of the migrants and 85.3% were in working age 
between 15 and 64 years. Migrants were concentrated in urban areas and 
more than half lived in the Helsinki and Uusimaa region. 30 In 2015–2016, 
the number of asylum seekers to Finland increased nearly ten-fold with the 
relative increase being among the highest in Europe. The majority of these 
asylum seekers were born in Iraq, Afghanistan and Syria, and a quater of 
them were children. 31 
Review of the literature 
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2.1.3 MIGRATION, HEALTH AND INFECTIOUS DISEASES
Migration has various impacts on health on an individual level among the 
migrants and on a population level both in the countries of origin and 
destination 2, 6, 7, 18. Immigration of healthy migrants and “brain gain” of 
health professionals are examples of population health benefits of migration 
7, 18. On the other hand, migrants might have specific vulnerabilities that 
translate into increased morbidity. Forced migration typically exacerbates 
the health risks especially among the vulnerable populations: children, 
women, elderly and the disabled 1. Reports on migrant health are dependent 
on the heterogeneity of the migrant populations, reference groups and health 
concerns of interest 2, 4, 19. 
Epidemiology of infectious diseases is influenced by interlinked global 
megatrends of globalization, population movements and environmental 
changes. Air travel enables human, livestock, food as well as accompanying 
infections to cross the globe within hours. Population movements induce 
demographic changes and the risk profiles for infection might differ between 
the newcomers and the native populations. Moreover, environmental 
changes linked to global warming and urbanization might facilitate the 
emergence of some infections, especially zoonoses. 19, 32 
On an individual level, migrants’ health and risk for infectious diseases is 
influenced by various determinants for health, some of which are migration-
specific (Figure 1) 2, 6, 21, 23, 33-35. Some of the migration-specific determinants 
for health occur only at certain phases of the migration cycle. Some –- such 
as health system coverage –- are present at every phase of the transition. 19 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Socio-demographic determinants for infectious diseases among migrants at four 
steps of the migration cycle 2, 6, 7, 21, 23, 33-36. AAA = Access, Affordability, Availability.
1. Pre-departure
? Social factors incl. poverty
? Health systems (AAA)
? Infection prevalence
? Environmental factors and
conflict
4. Return
? Type of travel
? Travel health services
? Vaccinations and 
prophylactic medications
3. Intergration
? Social factors
? Health literacy
? Migrant communities
? Health systems (AAA)
2. Transit
? Migration pathways
? Social factors, incl. over-
crowding
? Health systems (AAA)
? Exploitation
Individual
? Socio-demographic determinants
? Health literacy
? Behaviours
? Push and pull factors for migration
  
Migration has increased the heterogeneity of epidemics of blood-borne and 
sexually transmitted infections in Europe as epidemiological characteristics 
such as transmission mechanisms partly differ between native and migrant 
populations,  37, 38. In most high-income, low-prevalence countries migrants 
are disproportionally affected by blood-borne and sexually transmitted 
infections and have become a key population for public health responses 4, 39-
42. Migrants are not considered to pose a threat to the spread of infectious 
diseases among the general population but are, however, themselves 
vulnerable to infections 9, 11. For example, a Dutch modelling study showed 
that migration influences above all the risk of HIV spread among migrants 43. 
Migration poses challenges to infectious disease surveillance since current 
surveillance and reporting systems are not well-adjusted to observe patterns 
of population movements 4, 34, 44, 45. As an example, only a small minority of 
EU/EEA countries are able to monitor the continuum of HIV care among 
migrants 46. 
2.2 BASICS OF HEPATITIS B AND C, HIV AND SYPHILIS 
Hepatitis B and C, HIV and syphilis are categorised as blood-borne and 
sexually transmitted infections as they are caused by micro-organisms that 
are transmitted either directly or indirectly from human to human through 
blood and during sexual contact. Direct transmission occurs during intimate 
contact or vertically from mother to child during pregnancy, delivery or 
breast-feeding (MTCT). Indirect transmission can occur through injecting 
drug use (IDU) or iatrogenically contaminated medical equipment or blood 
products. 12, 47, 48 
2.2.1 BASICS OF HEPATITIS B 
Hepatitis B is a viral hepatitis infection caused by a double-stranded DNA-
virus belonging to the Hepadnaviridae family. Eight major viral genotypes 
(A to H) have been identified 49. Hepatitis B virus (HBV) was first identified 
as a causative agent of serum hepatitis in 1965 50.  
A third of acute infections are symptomatic and less than 1% result in 
fulminant acute hepatitis B 50. Extrahepatic manifestations of infection also 
occur 50. Development of chronic hepatitis B (CHB) is inversely associated 
with age; 90% of perinatally infected neonates develop CHB in comparison to 
less than 5% of newly infected adults 51, 52 Spontaneous transition occurs 
between the four clinical phases of CHB: immune-tolerance, immune-
clearance, immune-control and immune-escape 49-51, 53.  
Prognosis of CHB is influenced by HBV viral load, infection activity, viral 
genotype, age, gender, genetic factors, as well as other comorbidities and risk 
behaviours and is directly related to the development of cirrhosis 12, 50, 51, 54.  
Approximately 20–30% of the people living with CHB develop severe 
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sequelae: liver dysfunction, cirrhosis and hepatocellular carcinoma 50, 55. The 
five-year cumulative probability of developing cirrhosis among HBsAg-
positive ranges from 8 to 20% and five-year survival among patients with 
HBV-induced cirrhosis between 30–85% 12, 49.  
HBV is transmitted through blood, sexual contact or saliva 12. MTCT and 
early-childhood horizontal transmission are the most common modes of 
transmission in high-prevalence areas whereas in low-prevalence settings, 
HBV transmits typically through sexual contact or percutaneously 50.  
Screening of CHB is often based on the serological detection of surface 
antigen (HBsAg). A combination of different HBV-specific antigens and 
antibodies, and HBV-DNA, are used to identify different phases of HBV 
infection and determine whether a person is immune to HBV 12, 49, 55.  
Hepatitis B vaccine has been available for primary prevention globally since 
1982 and was included in the national vaccination program in Finland in 
1993 56, 57. In 2009 the World Health Organization (WHO) recommended 
universal hepatitis B vaccination of all infants 58. Hepatitis B 
immunoglobulin in conjunction with hepatitis B vaccine can be administered 
for post-exposure prophylaxis 12, 55.  
Nucleoside or nucleotide analogue and interferon-based therapy is 
available for the treatment of CHB 59. Usually indefinite regimen is required 
but treatment cessation might be considered for some patients 59. WHO 
recommends antiviral treatment of CHB for patients with cirrhosis or with 
CHB/HIV-coinfection, and for adults presenting with high viral activity 55. 
2.2.2 BASICS OF HEPATITIS C 
Hepatitis C infection is caused by a single-stranded RNA-virus belonging to 
the Flaviviridae family. Hepatitis C virus (HCV) infects mainly liver cells. 60 
The virus was first identified in 1989 61. Seven HCV genotypes have been 
identified with distinct distribution according to geographical origin and 
transmission mode 60, 62.  
Acute hepatitis C is asymptomatic in 90% of those infected and fulminant 
acute hepatitis is rare. Approximately 20% resolve the infection 
spontaneously. 60 Approximately 10–40% of those with chronic hepatitis C 
(CHC) will develop disease sequelae namely fibrosis, hepatocellular 
dysfunction, cirrhosis, and hepatocellular carcinoma 60, 63. Extra-hepatic 
manifestations occur in 38–76% of patients with CHC 12, 60, 64. 
Disease progression has been associated with older age, male gender, 
elevated transaminases, viral genotype, HBV and HIV coinfection and 
excessive alcohol intake 60, 61, 64. Of patients with CHC-related cirrhosis, 1–5% 
will develop hepatocellular carcinoma annually. The development of 
carcinoma has been associated with level of HCV viremia, activity of the 
hepatitis and viral genotype. 63  
  
Hepatitis C is mainly transmitted through unsafe medical procedures and 
injection equipment 65. The probability of MTCT is 3–10% 60, 65. Risk of 
heterosexual transmission of HCV has been estimated below 5% per sexual 
contact. Increasing numbers of HCV transmissions among non-IDU men 
who have sex with men (MSM) especially in the presence of HIV coinfection 
have been reported globally during the last decades. 66  
Detection of antibodies to HCV (HCVAb) is used for screening and CHC 
diagnosis is based on identification of HCV RNA 64. WHO recommends 
evaluation of all HCV-infected for treatment and from 2015 the direct-acting 
antivirals have become the standard of care 60, 67. Direct-acting antivirals are 
highly effective in achieving sustained virological response among different 
HCV genotypes in over 90% of patients but more evidence is needed to 
support long-term benefits on HCV-related morbidity and mortality 68, 69. 
2.2.3 BASICS OF HIV 
Human immunodeficiency virus (HIV) infection is caused by a single 
stranded RNA-virus belonging to the Retroviridae family 12. Two types of 
virus (HIV-1 and HIV-2) have been identified. HIV-1 is divided into four 
groups. HIV-1 group M viruses cause the majority of infections globally and 
are further categorized into subtypes and circulating recombinant forms that 
have distinct geographical distributions. 70 
HIV targets CD4-positive T-lymphocytes leading to a depletion of the 
CD4-positive cell reservoir and immune dysfunction, and is accompanied by 
a generalized immune activation 71, 72. There are three stages of HIV 
infection: acute, chronic and acquired immunodeficiency syndrome (AIDS). 
Acute HIV infection might involve flu-like symptoms 73. AIDS, the most 
advanced stage of HIV infection, is characterized by the presence of 
opportunistic illnesses 73-75.  
Natural disease progression varies greatly between individuals and 
especially age at seroconversion 71, 73, 76. Median time of survival after HIV 
seroconversion without treatment is approximately 10 to 12 years 76.  
Although sexual transmission of HIV is the major mode of HIV 
transmission globally, the probability of infection per sexual contact is low, 
ranging between 0.003% and 7.5% with highest risk associated with 
receptive anal intercourse 12, 73. HIV is transmitted more effectively through 
blood transfusion (estimated risk over 90% per contact), MTCT (23–40%) 
and needle sharing (0.63%) 73, 77. Risk of sexual transmission of HIV is 
increased by high HIV viral load, presence of other sexually transmitted 
infections, pregnancy and lack of male circumcision 12, 72.  
Diagnosis of HIV is based on detection of HIV-specific p24 antigen and 
antibodies (HIVAgAb). Nucleic acid amplification test (NAAT) is used in 
assessment of a recent HIV infection and MTCT. 73 Plasma viral load and 
CD4 count are used for staging of the infection and monitoring of treatment 
71, 73.  
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Since the introduction of zidovudine in late 1980s, there has been a 
dramatical increase in the availability, efficacy and tolerability of new classes 
of antiretroviral drugs 72, 73, 78. Antiretroviral therapy with combination 
regimen of antiretroviral drugs (cART) significantly reduces HIV-related 
morbidity and mortality, and prevents further transmission 78, 79. The life 
expectancy of HIV-infected individuals on cART is estimated to be nearly the 
same as for non-HIV-infected persons especially if cART is initiated early, 
adherence to treatment is high and other risk factors are controlled 78. 
Current guidelines recommend universal initiation of cART after diagnosis 
irrespective of the clinical stage of the disease or CD4 count 79, 80.  
2.2.4 BASICS OF SYPHILIS 
Syphilis is a bacterial infection caused by Treponema pallidum subspecies 
pallidum spirochete and is related to other pathogenic treponemes that cause 
non-venereal infections 81, 82.  
Clinically syphilis can be classified into incubating, primary, secondary 
disseminated, latent and tertiary late phases. Primary syphilis involves the 
development of a painless ulcerative lesion at the site of inoculation. 12 At 
secondary stage, syphilis spirochetes disseminate in the body and 
parenchymal, constitutional and mucocutaneous manifestations can occur 12, 
83. Clinical manifestations of syphilis are absent in the latent phase 83. 
Tertiary phase symptomatic syphilis is characterized with severe sequelae 
including cardio-vascular and neurological complications 82, 83. If untreated, 
15–40% of syphilis infected will develop late complications 83. Congenital 
syphilis has been associated with higher risk of stillbirth, prematurity and 
neonatal death and more than half of pregnancies in women with syphilis 
will develop adverse outcomes 84.  
Sexual transmission of venereal syphilis takes place through lesion 
contact during primary or secondary phases of infection 82, 83. MTCT can 
occur at any phase of the infection 81, 83. Blood-borne transmission of syphilis 
is rare 83.  
Diagnosis through direct detection of syphilis spirochete is possible 
during primary, secondary and early congenital phases of infection using 
dark field microscopy, direct immunofluorescence or NAAT 12, 85, 86. 
Serological testing is used at every stage of the infection. The traditional 
algorithm for syphilis serology testing combines a non-treponemal screening 
test with a treponemal confirmatory test. A reverse algorithm applies the 
opposite 85-87. Non-treponemal tests, such as Venereal Disease Research 
Laboratory test, use non-treponemal reagins (cardiolipin, lecithin, 
cholesterol) whereas treponemal tests, such as treponemal agglutination or 
immunoassays, apply Treponema-derived reagins (lysates or recombinant 
antigens) 85. In Finnish antenatal screening (ANS), the reverse algorithm 
  
replaced syphilis screening with non-treponemal tests (Venereal Disease 
Research Laboratory test, Cardiolipin) in 2005 87, 88. 
Benzathine penicillin is recommended as the first-line treatment for 
syphilis 12, 89. 
2.2.5 COINFECTIONS 
Coinfections of hepatitis B and C, HIV and syphilis influence disease 
prognosis and morbidity. Most significantly HIV accelerates the natural 
history of hepatitis B and C, and syphilis 51, 65. Interactions among CHB/HIV-
coinfected are two-directional; HIV/CHB coinfection is associated with 
increased risk of liver-related mortality compared with either monoinfection 
alone, and vice versa; several studies indicate that underlying HBV infection 
also accelerates HIV progression and related morbidity 90.  
Patients with CHC/CHB or CHC/HIV coinfections have increased risk for 
developing liver fibrosis and cirrhosis 65, 91. The probability of MTCT of HCV 
is increased among mothers with HIV 60. Patients with HIV/syphilis 
coinfection present with higher viremia, lower CD4 counts, persistent 
primary and secondary syphilis and rapid progression to tertiary syphilis 12, 
83. 
2.3 EPIDEMIOLOGY OF HEPATITIS B AND C, HIV AND 
SYPHILIS 
In many low-prevalence countries, migrants are disproportionally affected by 
blood-borne and sexually transmitted infections 4, 92, 93. However, 
assessments of infectious disease burden among migrants face several biases 
resulting in both under- and over-estimation of the burden 94. Incidence data 
are essentially dependent on testing strategies 95.  
2.3.1 EPIDEMIOLOGY OF HEPATITIS B 
Globally, approximately 250 million persons have CHB and global overall 
HBsAg seroprevalence was 3.6% in studies performed in 1957–2013 96. A 
recent modelling study concluded a similar prevalence for 2016 at 3.9% 97. 
The majority of the infected are male 98, 99. In 2016, over 400,000 suffered 
from hepatitis B-associated carcinomas and 686,000 persons died of 
hepatitis B-related complications in 2013 100, 101.  
Trends in CHB prevalence over time are heterogeneous across regions 
and currently the most affected areas are Western-Pacific (over 95 million 
infected) and Africa (over 75 million infected) 96, 102, 103. Countries can be 
divided into categories based on very low (<0.5%), low (<2%), low 
intermediate (2–4.99%), high intermediate (5–7.99%) and high (≥8%) CHB 
endemicity 55, 92.  
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Population growth and ageing result in increasing global CHB burden 
despite the decreasing hepatitis B incidence achieved with vaccinations 101, 
103. Less than 10% of those infected with CHB are estimated to have been 
diagnosed 104. Approximately 10% of HIV patients are coinfected with CHB 
and 5–20% of patients with CHB are concurrently infected with HCV 50, 90, 
105. 
Migrants in low CHB prevalence countries have a significantly higher 
CHB burden than other risk groups, such as people who inject drugs (PWID). 
A systematic review and a meta-analysis estimated an overall global HBsAg 
seroprevalence among migrants at 7.2% with highest prevalence rates among 
migrants from highly endemic regions, namely East Asia and Pacific and 
Sub-Saharan Africa (SSA). 106 Another meta-analysis found an HBsAg 
prevalence of 3.5% among migrants to the USA 107. 
Europe is considered a region with low CHB endemicity 96, 103. CHB 
prevalence in Europe has been estimated at 1.8–2.1% with 13 to 18.5 million 
individuals infected 41, 96, 108. CHB prevalence among general populations in 
the EU/EEA was estimated at 0.9% as two-thirds of the CHB cases in Europe 
live outside the EU/EEA area 40, 108, 109. Notification incidence of CHB in 
EU/EEA has steadily increased, standing at 8.7 per 100,000 in 2016 110, 111. 
Conversely, the incidence of acute hepatitis B decreased in the EU/EEA 
during the last two decades, most likely due to increasing vaccination 
coverage 111, 112. Among the notified HBV cases in 2016, male-to-female ratio 
was 1.7:1 and nearly a third was identified among 25–34 year olds 111.  
Heterosexual transmission was the most common (30.2%) mode of 
transmission for acute hepatitis B in EU/EEA in 2016. For CHB, nosocomial 
(32.6%) and MTCT (31.6%) transmissions were most prevalent although the 
completeness of information on transmission mode was poor. 111 The highest 
HBsAg seroprevalence in EU/EEA has been observed among incarcerated 
persons (0.3–25.2%), PWID (0.5–6.1%) and MSM (0–1.4%) 113.  
In EU/EEA every fourth CHB infection was estimated to affect migrants 
from HBV-endemic countries 40, 92. Previous reports have shown HBsAg 
seroprevalence rates among migrants in Europe to range from 1.0 to 15.4% 
and overall HBsAg seroprevalence among migrants from endemic countries 
in the EU/EEA was estimated at 5.5% 40, 41, 114. Migrants from endemic 
countries are considered the most important risk population for MTCT of 
HBV in EU/EEA 115. 
In Finland, prevalence of CHB among the general population is assumed 
to be very low (<0.2%) although no recent seroprevalence assessments 
among the general population are available 110, 116. HBsAg seroprevalence was 
0.14% among pregnant women in 2005–2009 88. During 2004–2012, 59.8% 
of CHB cases were notified among men, 81.5% had a foreign origin and 3.3% 
had a HCV coinfection 57. In 2017, notification incidence of CHB was 4.7 per 
100,000 5.  
To date, no studies have assessed the CHB prevalence among general 
migrant populations in Finland; however two meta-analyses have provided 
  
an indication. Rossi et al. provided an estimate of 6.4% CHB prevalence 
among all migrants whereas Ahmad et al. estimated a 5.7% CHB prevalence 
among migrants from HBV-endemic countries (HBsAg ≥2%) in Finland 40, 
106. Three percent of pregnant migrant women in irregular situations in 
Helsinki during 2014–2018 were diagnosed HBsAg positive 117. 
2.3.2 EPIDEMIOLOGY OF HEPATITIS C 
Global age-adjusted general population HCVAb seroprevalence was 
estimated to have increased from 2.3% in 1990 to 2.8% in 2005 among 
studies published during 1980–2007 118. A more recent review of studies 
published in the 21st century reported 2.0% HCVAb prevalence among 
general population adults and 1.6% among all age groups. The prevalence of 
viremic CHC among all ages was estimated at 1.1%, corresponding to 80 
million chronically infected. 119 According to the Global Burden of Disease 
Study, CHC accounted for 704,000 deaths in 2013 and nearly 200,000 
developed CHC-associated carcinomas in 2016 100, 101.  
The highest CHC prevalence has been reported in Central and East Asia, 
Middle East and North Africa, and China, Egypt, India, Nigeria, Pakistan and 
Russia account for more than 50% of all infections globally 118, 119. Regional 
differences in CHC prevalence are explained by demographic differences, 
concentration of cases in certain age groups or sub-populations, transmission 
patterns and coinfection with HIV 61, 118, 119. The proportion of infected 
children is higher in low-income countries (54%) compared to high-income 
countries (4%) 119. 
Countries can be divided into categories based on HCV prevalence among 
the general adult population: very low (<1%), low (1–2%), intermediate (2–
3%), high (3–5%) and very high (>5%) endemicity 120. The European Centre 
for Disease Prevention and Control (ECDC) defines countries as having low 
(<1%) or high (≥1%) HCV endemicity 92. 
Globally, the most CHC-affected populations include injecting and other 
recreational drug users, patients frequently receiving blood products, paid 
blood donors and incarcerated and homeless persons 61, 119, 121. Global HCVAb 
seroprevalence among migrants from intermediate or high HCV-endemic 
countries was estimated at 1.9%, with highest seroprevalence rates among 
migrants from South Asia, SSA and Eastern Europe 120.  
Global HCV incidence has decreased during the last decades mostly due 
to developments in harm reduction services and improved blood and 
injection safety. However, due to population growth and ageing, the overall 
HCV disease burden has increased since 1990. 101 Up to 80% of HCV-infected 
remain undiagnosed 104. The prevalence of CHB among patients with CHC is 
approximately 2–10% 105. 
In Europe, HCVAb prevalence among the general population was 
estimated at 1.4% and at 1.1% within the EU/EEA 39, 41, 109. A modelling study 
estimated the prevalence of viremic CHC at 0.64% in EU/EEA in 2015 122.  
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Notification rate of HCV was 7.4 per 100,000 with male-to-female ratio 1.9:1 
and 51.6% of cases notified among the 25–34 year olds in EU/EEA in 2016 
123. The highest HCVAb seroprevalence rates in EU/EEA countries have been 
observed among incarcerated persons (4.3–86.3%), PWID (13.8–84.3%) and 
MSM (0–4.7%) 113. 
Migrants from HCV-endemic countries (HCVAb≥1%) were estimated to 
account for 14% of the total CHC burden in EU/EEA 39, 92. Nearly 80% of 
migrants in EU/EEA have arrived from HCV-endemic countries and 
approximately 30,400 migrants with CHC entered the EU/EEA in 2015 39, 122. 
HCVAb seroprevalence among migrants in Europe ranges between 0 to 
23.4% 41, 114. In EU/EEA, HCVAb prevalence among migrants from endemic 
countries was estimated at 2.3% with 1.6% of the migrants being viremic 39. 
Hepatitis C prevalence among the general population in Finland was 
estimated at 0.3% in 2013 based on surveillance data. Of all notified HCV 
cases in Finland during 1995–2013, 11.7% were born abroad. 124 A systematic 
review and meta-analysis predicted an HCVAb prevalence in Finland of 
0.68% and a modelling study estimated a prevalence of viremic CHC in 
Finland of 0.4% in 2015 119, 122. HCVAb seroprevalence was 0.64% among 
pregnant women attending ANS in 2010 124. In 2017, hepatitis C notification 
incidence was 20 per 100,000, the majority of infections were in age group 
20–24 year olds, 65% of infections were observed among men and 16% had 
foreign origin 5. A meta-analysis predicted the CHC prevalence among 
migrant populations from HCV-endemic countries (HCVAb ≥1%) in Finland 
to be at 1.9% 39. 
2.3.3 EPIDEMIOLOGY OF HIV 
Global age-standardized HIV prevalence was 0.40% in 2013 125. In 2017, 36.9 
million persons were living with HIV, approximately 1.8 million persons 
were newly infected and 0.9 million died of HIV/AIDS-related conditions 
with tuberculosis (TB) being the leading single cause of death 126, 127. Global 
HIV incidence has decreased since 1997 and mortality since 2005 mainly due 
to rapidly improving ART coverage 126. Globally, HIV infections are mainly 
diagnosed among young adults and occur equally among both sexes 125. 
Worldwide HIV prevalence is increasing due to improved prognosis achieved 
with ART 72. In 2017, 75% of people living with HIV (PLWH) were aware of 
their status and 59% had access to ART 127. Globally, the populations most 
vulnerable to HIV include sex workers, MSM, incarcerated persons, PWID 
and transgender women 128-131.  
Countries with HIV prevalence over 1% among the general adult 
population are defined as having generalized epidemics. Prevalence over 5% 
in any population sub-group is defined as a concentrated epidemic. Countries 
with general population prevalence less than 1% and without any 
concentrated epidemics are categorized as having mixed HIV epidemics. 132 
  
The highest HIV prevalence has been observed in SSA (1.33–11.85%), the 
Caribbean and Latin America (0.11-0.50%), Eastern Europe (0.2%) and Asia 
(0.03–0.2%) 125. At the same time, the burden of HIV is highest in SSA and 
Asia and the Pacific with 25.7 million and 5.2 million PLWH, respectively, 
and 0.66 million and 0.17 million deaths in 2017, respectively 133.  
In Europe, overall HIV prevalence was 0.16–0.34% in 2016 with 1.3–2.7 
million PLWH 98, 134. According to UNAIDS estimates, adult prevalence of 
HIV in Eastern Europe and Central Asia was 0.8% in 2017 135. In WHO 
European region, 160,000 people were diagnosed with HIV in 2016 of whom 
80% were notified outside the EU/EEA. The majority of cases were in the 
30–39 year age group and male-to-female ratio was 2.3:1. 136  
Heterosexual transmission was the most common mode of transmission 
in Eastern Europe while the majority of transmissions in Central and 
Western Europe occurred among MSM. In Eastern Europe, the notification 
incidence of HIV has nearly doubled during the last decade and the highest 
rate in 2016 was observed in Russia. 136 The HIV epidemic in Eastern Europe 
and Central Asia is largely driven by IDU and their bridging populations, 
limited harm-reduction services, suboptimal ART coverage and 
criminalization and stigmatization of MSM 137. On average 83% of PLWH in 
EU/EEA have been diagnosed and the rest are unaware of their infection 138. 
Migrants represented 38% of notified HIV infections in EU/EEA during 
2007–2012 and the majority were from SSA (53%). During 2007–2012, the 
number of annual HIV notifications among migrants decreased by 14%, 
largely reflecting a decrease in HIV notifications among migrant women from 
SSA. 139 Estimates of HIV prevalence among general migrant populations in 
Europe range between 0 and 14.0% depending on the reporting country and 
migrant population 140-142.  
In comparison to native populations, migrants with newly diagnosed HIV 
in EU/EEA were younger and more commonly women. Heterosexual 
transmission was the most common transmission category among migrants 
from Africa, Eastern Europe, South Asia, and the Caribbean, whereas MSM 
transmission was more common among migrants from the Americas, Central 
and Western Europe, East Asia and the Pacific and Oceania. 139 Among 
heterosexual and perinatally acquired HIV transmissions, the majority of 
infections occurred among migrants (58 and 57%, respectively) 4, 42.  
Migrants from endemic countries are considered the population most 
vulnerable to MTCT of HIV in EU/EEA 115.  
In Finland, approximately 170 new HIV infections are reported annually. 
In 2018, HIV notification incidence was 2.8 per 100,000, the majority of 
infections were diagnosed among 35–39 year olds, 68% of cases were male 
and 59% had foreign origin. Heterosexual transmission represented 36% and 
MSM transmission 26% of cases. 143 According to national estimates, there 
were approximately 3,800 PLWH in Finland in 2017 144, 145. No 
seroprevalence assessments among the general population have been 
performed but the seroprevalence of HIVAgAb among pregnant women was 
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0.027% during 2005–2009 88. Of the pregnant women with HIV in Finland, 
the proportion of migrants increased from 18 to 75% from 1999 to 2013 146. 
HIV prevalence among pregnant migrant women in irregular situations in 
Helsinki during 2014–2018 was 5% 117. 
2.3.4 EPIDEMIOLOGY OF SYPHILIS 
The global prevalence of active syphilis defined as having both treponemal 
and non-treponemal test positivity was estimated at 0.5% in 2012 with nearly 
18 million infected individuals and 5.6 million incident adult cases annually 
147. According to Global Burden of Disease study estimates, global syphilis 
prevalence was higher among men (0.6%) as compared to women (0.4%) 98. 
Although the global burden of syphilis has decreased during the last decades, 
there were still approximately 137,000 deaths due to neonatal syphilis in 
2013 99, 147, 148. 
Low-income countries have the highest prevalence rates and the burden 
of syphilis is highest in Africa with 1.8% of the population infected 147. 
Globally, female sex workers and MSM bear a substantial burden of syphilis 
and have been recognized as key populations for syphilis prevention 149. 
Syphilis prevalence among migrants has been reported at 0.4–6.0% with 
highest seroprevalence rates among migrants from SSA, East Asia and the 
Middle East and North Africa 114, 150, 151. 
In EU/EEA, syphilis notification incidence was 6.1 per 100,000 in 2016 
and has been on the rise since 2010. Male-to-female ratio of reported 
infections was 7.9:1 in 2016 and has steadily increased since 2000. Since 
2007, notifications among older age groups have continuously increased with 
one-third of infections in 2007–2016 notified among persons 45 years or 
older. The proportion of MSM transmissions among all transmission 
categories has increased since 2010 and was 66% in 2016. Every third 
incident syphilis case, and 41% of the cases among MSM with known HIV 
status had HIV coinfection. 152 Approximately 8.5% of the syphilis cases in 
EU/EEA since 2000 have been reported among migrants. Heterosexual 
mode of syphilis transmission was more common among migrants in 
comparison to natives in the EU/EEA (57 vs. 35% respectively). 4 
In Finland, notification incidence of primary and latent syphilis was 3.4 
per 100,000 in 2018. The majority of infections in 2018 were diagnosed 
among 30–35 year olds, males represented 79% of the notified cases and 
49% had foreign origin. 153 A syphilis outbreak was observed in Finland in 
1995 after the dissolution of the Soviet Union and increased travel to Russia. 
Majority of the infected had Finnish origin (83%) and half of the infections 
occurred outside of Finland. 154 In recent years, the majority of infections 
among native Finns have occurred in Finland 5. TrpaAb seroprevalence was 
0.11% among pregnant women attending antenatal follow-up in Finland 
during 2005–2009 88. One syphilis case was identified among 60 pregnant 
  
migrant women in irregular situations in Helsinki, Finland, during 2014–
2018 117. 
2.4 PERSPECTIVES ON HEPATITIS B AND C, HIV AND 
SYPHILIS AMONG MIGRANTS 
Based on current evidence on epidemiology of hepatitis B and C, HIV and 
syphilis among migrants, three recurrent themes seem to emerge: 
 
? Infectious disease prevalence among migrants mirrors the general 
population prevalence in countries of origin 
? Healthy migrant phenomenon: infectious disease prevalence among 
migrants is lower than among the general population in countries of 
origin or of current residence 
? Migrants are vulnerable to infections post-migration in the current 
countries of residence 
2.4.1 MIRRORED EPIDEMIOLOGY IN THE COUNTRIES OF ORIGIN
Evidence suggests that the epidemiology of hepatitis B and C, HIV and 
syphilis among migrants mirrors that of countries of origin and that the risk 
factors for infection among migrants in current country of residence (CCOR) 
and general population in countries of origin are similar 139. Mirroring has 
been reported with respect to seroprevalence rates, pathogen genotype 
distribution and transmission categories 37, 106, 139, 155-157.  
In a systematic review and a meta-analysis, CHB prevalence was higher 
among migrants from high-prevalence regions, that is East Asia and the 
Pacific (11.3%) and SSA (10.3%), and lower among migrants from low-
prevalence regions such as Latin America and the Caribbean (1.7%) 106. 
Another review identified highest HBsAg seroprevalence rates among 
refugees and asylum seekers from high-prevalence areas (SSA and Asia) 150. 
A large cross-sectional study among 95,000 asylum seekers in Germany 
concluded that observed HBsAg and HIVAgAb seroprevalences mirror the 
prevalences in the countries of origin 158.  
A Danish register-based cohort study found highest risk for HIV among 
migrants from SSA followed by Latin America and the Caribbean, Southeast 
Asia and Eastern Europe and Central Asia 159. Female refugees and asylum 
seekers from Africa had higher odds of testing positive for HIV among all 
refugees and asylum seekers to the UK in 2013–2017, exemplifying the 
burden of HIV among women in Africa 126, 160. Although overall immigration 
from Africa to Europe has increased during the 21st century, the number of 
notified HIV cases among migrants from SSA in EU/EEA has decreased 
during 2007–2012 3, 139. The phenomenon may reflect the increasing ART 
coverage in SSA 139.  
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Furthermore, transmission mechanisms of HIV among migrants from 
SSA mimic epidemics in the countries of origin 139. In contrast, MSM 
transmissions are overrepresented among Latin American migrants in 
EU/EEA in comparison to those reported in the countries of origin 
suggesting a possible selective migration of MSM from these areas 139, 161. 
HBV, HCV and HIV viral strains among migrants in Europe are similar to 
those in the countries of origin 37, 155-157.  
2.4.2 HEALTHY MIGRANT PHENOMENON
Healthy migrant phenomenon refers to the observation that migrants might 
have better health outcomes in comparison to general populations in the 
countries of origin or to that of the CCOR. The phenomenon is due to 
selective migration of healthier individuals or distribution of better health 
characteristics among the migrant populations than among the permanent 
residents in the CCORs. 6 
In Finland, two register-based cohort studies have found that migrants 
had a significantly lower mortality risk in comparison to Finnish-born 
persons 162, 163. The mortality benefit was especially pronounced among men 
from Middle East and North Africa, SSA and Asia, and among women from 
FSU, Middle East and North Africa, and Asia, and among migrants with low 
income 162, 163. Mortality was lower for all causes of death although no 
separate analyses were performed for infectious diseases 162. Migrants’ 
mortality benefit might also be due to the so-called “salmon bias” that results 
from selective return migration of older persons or individuals with terminal 
illnesses resulting in mortality underreporting in the death statistics of the 
CCORs 162, 164. 
Several observations from infectious disease seroprevalence surveys 
among migrants suggest a lower seroprevalence in comparison to general 
populations in countries of origin. A recent literature review found nine of 14 
studies reporting lower HBsAg prevalence among migrants in EU/EEA than 
general population estimates in countries of origin 40. Lower HBsAg 
seroprevalence rates were also observed among refugees and asylum seekers 
to the UK during 2013–2017 in comparison to in-country rates 160. In 
contrast, another review showed no difference in the HBsAg seroprevalence 
between in-country general population and migrants in the USA 107.  
Evidence supporting the healthy migrant phenomenon regarding CHC is 
not as clear. A review on HCVAb prevalence among migrants in EU/EEA 
found three out of 12 studies showing lower HCVAb seroprevalence among 
migrants in EU/EEA in comparison to seroprevalence estimates among 
general population in countries of origin, and in seven studies the HCVAb 
seroprevalence was comparable to that in the countries of origin 39. A later 
cross-sectional study among refugees to the UK found substantial variation 
among the CHC prevalence rates in comparison to in-country estimates 160. 
  
For HIV, a large collaboration cohort study demonstrated lower mortality 
among migrant PLWH in Europe, Canada and USA in comparison to native 
PLWH. Differences in mortality patterns among migrant and native PLWH 
were explained by differences in non-AIDS mortality but the authors 
recognise healthy migrant phenomenon and salmon bias as possible 
contributing factors. 165 Similarly, a European cohort study demonstrated 
lower or comparable mortality among heterosexual migrant men living with 
HIV in comparison to native men. However, higher mortality was observed 
among heterosexual migrant men from Latin America and women from the 
Caribbean. 166  
A recent large British cross-sectional pre-migration prevalence study 
identified generally higher HIV prevalence rates among refugees and asylum 
seekers as compared to in-country prevalence rates. Syphilis seroprevalence 
among the same study population, on the other hand, was mostly lower than 
among general populations in the countries of origin. 160 
Among the major migrant populations in Finland, recent reviews on in-
country and migrant population HBsAg seroprevalence rates do not clearly 
support the healthy migrant phenomenon (Table 1). Ott et al. estimated an 
HBsAg seroprevalence of 4.62% in Russia, which is significantly higher than 
the estimate of 2.89% among Russian-origin migrants provided by Kowdley 
et al. 102, 107. There is substantial variation in HBsAg seroprevalence rates 
between countries of FSU: in some countries the in-country HBsAg 
seroprevalence seems to be significantly lower (Armenia, Azerbaijan, Estonia 
and Ukraine) and in others higher (Kyrgyzstan, Moldova, Turkmenistan) 
than among FSU-origin migrants 40, 96, 97, 102, 107. Conversely, Kowdley et al.’s 
estimate of 3.10% HBsAg seroprevalence among migrants from Iran is 
significantly higher than the in-country estimates provided by other 
researchers 96, 97, 102, 107. 
2.4.3 MIGRANT-SPECIFIC VULNERABILITIES TO HEPATITIS B AND C, 
HIV AND SYPHILIS 
2.4.3.1 Vulnerable migrant populations 
Some migrants might be especially vulnerable to hazardous health outcomes 
including infectious diseases. Factors associating with increased vulnerability 
may derive from genetic, biological, environmental, behavioural or socio-
demographic determinants for health and disease. 6 Populations in 
vulnerable situations generally include children, elderly, disabled persons, 
sexual minorities, detainees, forced migrants, victims of exploitation and 
migrants in irregular situations 167. Some migrants might have several, 
overlapping vulnerabilities to infection 141. Here, vulnerabilities to infection 
during transit and after arrival are discussed. Of note, however, is that they 
might occur at any point of the migration cycle (Figure 1). 
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2.4.3.1.1 Labour migrants 
A systematic review identified multilevel determinants for the HIV risk 
among labour migrants and circular workers. Frequency of seasonal work, 
longer residency away from the family, migration from rural to urban 
environment as well as alcohol and drug use were associated with increased 
risk for HIV, other STIs and risky sexual behaviours. 168 Seasonal workers 
and circular migrants also experience difficulties in continuity of healthcare 
and have a higher risk for treatment interruptions 169. Epidemiology of 
hepatitis B and C, HIV and syphilis has not been previously studied among 
labour migrants in Finland. 
 
2.4.3.1.2 Migrant women 
Globally, women represent more than half of the PLWH and have higher 
HIV-related mortality in younger age groups despite having higher ART 
coverage in comparison to men 126, 170. Women’s vulnerabilities to infection 
relate to biological, behavioural and socio-demographic factors 170. 
Migrant women in high-income counties are disproportionately affected 
by HIV due to factors such as sexual exploitation and difficulties in 
negotiating condom use 142. In EU/EEA, women represented 63% of HIV 
cases among migrants in 2007–2012, whereas the majority of infections 
among the general population are observed among men 136, 139. Women 
represented 80% of HIV cases among refugees and asylum seekers to the UK 
in 2013–2017 160. 
In a large European cohort study, 80% of HIV-infected pregnant women 
with a singleton live-birth delivery in 2002–2012 had migrant origin. 
Migrant women were more likely to be diagnosed with HIV during antenatal 
follow-up and with lower CD4 cell levels in comparison to native women, and 
had also a higher risk for HIV diagnosis late in pregnancy. 171 Similar 
observations have been made in Finland, where migrant mothers with HIV 
were diagnosed more often in late pregnancy and with a later stage of disease 
in comparison to Finnish-origin mothers with HIV 146. An earlier literature 
review of the ECDC identified several studies on migrant and ethnic minority 
mothers having higher proportion of HIV diagnosis in pregnancy in 
comparison to native mothers 172. Delayed diagnosis in pregnancy among 
migrants might be explained by delayed entering to antenatal care observed 
in France, Germany and the Netherlands 173, 174.  
A Dutch register-based study among pregnant asylum seekers from SSA 
found higher HIV prevalence among single women and unaccompanied 
minors. The results also suggested a higher prevalence of HIV among asylum 
seekers as compared to general-population pregnant women in the countries 
of origin. 175 
Pregnant migrant women in irregular situations in Denmark had 
significantly higher HBsAg seroprevalence and a borderline higher HIV 
prevalence in comparison to documented migrants 176. Twelve percent of 
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pregnant migrant women in irregular situations in Helsinki, Finland, were 
diagnosed with hepatitis B, HIV or syphilis before delivery 117. 
 
2.4.3.1.3 Forced migrants 
Refugees and asylum seekers might be especially vulnerable to infections due 
to risk factors related to forced displacement and unselective migration. A 
systematic review and meta-analysis found that refugees and asylum seekers 
had 42% higher odds of being chronically infected with HBV in comparison 
to other migrants (9.6% and 5.1% respectively) 106. A Danish register-based 
cohort study found a higher risk for HIV among refugees, family-reunified 
migrants and asylum seekers in comparison to Danish-born controls 159. 
In contrast, no difference in HCVAb seroprevalence between refugees and 
other migrants has been observed 120. A recent review also found no 
differences in HBV, HCV and HIV prevalence by migration status but 
underlined that many studies lack information necessary for the 
differentiation of the reason for immigration 150. 
In 2016, approximately 40.6 million persons globally were victims of 
forced labour or marriage. Almost five million individuals were involved in 
forced sexual exploitation and 14% of them resided within Europe and 
Central Asia. 177 Human exploitation and trafficking might predispose 
migrants to blood-borne and sexually transmitted infections due to 
overcrowded and unhygienic travel and living conditions and sexual abuse 
178. Epidemiology of hepatitis B and C, HIV and syphilis among forced 
migrants in Finland has not been previously studied. 
 
2.4.3.1.4 Migrant MSM 
Migrant MSM are especially vulnerable to HIV due to racism, economic 
deprivation, sex work, substance use, high-risk sexual activity and limited 
access to services 179. Discrimination and stigmatisation of MSM in countries 
of origin might serve as a push factor for migration 139. During 2007–2016, 
the proportion of MSM transmission among HIV diagnoses notified among 
migrants in EU/EEA increased from 24% to 30% 136, 139, 180. In Finland, 59% 
of the MSM transmissions of HIV in 2018 were reported among migrants 143. 
During 2000–2010, fewer MSM transmissions of syphilis were reported 
among migrants (43%) than among natives (65%) in the EU/EEA 4. A 
marked increase in MSM transmission of syphilis has been observed in the 
EU/EEA in 2010–2016 but the proportion of migrants among these MSM 
transmissions has not been evaluated 152. Epidemiology of hepatitis B and C 
and syphilis among migrant MSM in Finland has not been described. 
 
2.4.3.1.5 Sex workers 
Sex workers are disproportionately affected by HIV globally and in EU/EEA 
129, 181. Increasing proportions of migrants are working in the sex and erotic 
industry in Europe 182. Migrant sex workers are especially vulnerable to STIs 
due to lower socio-demographic determinants for health, exploitation, 
  
irregular migration status, poor language skills and limited access to STI 
prevention services 182-185. However, in a British cross-sectional survey 
among female sex workers, migrant origin was not associated with higher 
prevalence of STIs although migrants reported higher rates of sexual risk 
behaviour and less service use in comparison to natives 182. 
Male sex workers are considered a hidden key population for STI control 
in many countries of Europe 183, 186. A cross-sectional study from the 
Netherlands showed that male sex workers had significantly higher risk for 
undiagnosed hepatitis B, HIV or syphilis in comparison to female sex 
workers. Although the majority of male sex workers in this study had migrant 
origin, migrant origin was not associated with new diagnoses of STIs. 186 
In a Finnish cross-sectional survey among sex workers in 2012–2013, two 
thirds of study participants had been born outside of Finland with Russia, 
Estonia and Thailand being the most common countries of origin. Migrant 
sex workers had significantly lower coverage of hepatitis A and B 
vaccinations and STI testing within the past 12 months in comparison to 
Finnish origin participants. HIV prevalence was 3% and HCV-Ab 
seroprevalence 5% without significant differences by origin. 187 
 
2.4.3.1.6 Injecting drug users 
Globally, approximately 9.0% of PWID are HBsAg-positive, 52.3% are 
HCVAb-positive and 17.8% have HIV. Concurrency of risk factors is common 
among PWID: a systematic review found that 59.7% had a history of 
incarceration, 16.8% recent commercial sex work and 37.4% reported recent 
unprotected sex with a non-regular partner. 188  
During 2007–2012, IDU-associated HIV infections among migrants in 
EUE/EEA represented less than 10% with the exception of migrants from 
Eastern Europe among whom IDU accounted for 25% of new the HIV 
infections 139. Among forced migrants in high-income countries, substance 
use prevalence rates of less than 5% have been observed. However, camp 
settings especially might increase risky behaviour. 189  
In another analysis based on the population-based Migrant Health and 
Wellbeing Survey in Finland (Maamu), prevalence of substance use among 
Kurdish, Russian and Somali migrants was rare and migrants reported 
significantly less alcohol use compared to the general population. 
Immigration as a minor and longer duration of residency in Finland 
increased the odds of lifetime cannabis use. 190 
 
2.4.3.1.7 Prisoners 
Prisoners and incarcerated persons are at risk for sexually transmitted and 
blood-borne infectious diseases due to criminalization and detention of 
PWID, continued drug injection and other risk behaviours in prisons in the 
absence of drug dependency treatments and harm reduction programmes. 
Globally, 4.8% of incarcerated persons in 2013 had CHB, 15.1% had CHC and 
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3.8% were living with HIV. The burden of infections was especially high in 
areas with generalized HIV epidemics or high prevalence of IDU. 191  
At the end of 2015, 15.1% of incarcerated persons in EU/EEA were 
foreigners 192. Incarcerated migrants from high-prevalence countries might 
contribute to the epidemics of blood-borne infections among prisoners in 
EU/EEA 113. Epidemiology of hepatitis B and C, HIV and syphilis among 
prisoners of foreign origin in Finland has not been assessed. 
2.4.3.2 Entitlement, access and retention in health services 
Migrants face specific barriers in entitlements, access and retention in care 
that hinder the achievement of optimal treatment cascades from testing to 
diagnosis to quality of care of blood-borne and sexually transmitted 
infections. Whereas entitlement to care refers to the existing legal 
frameworks of organizing healthcare for individuals without national health 
insurance, access to care is influenced by various other determinants at 
individual, healthcare provider and societal levels (Table 2). A recent 
systematic review summarised individual-level barriers and facilitators 
influencing acceptability and accessibility of infectious disease interventions 
among migrants 193. 
Depending on immigration status, some migrant groups might lack health 
insurance and have restricted entitlements to public health services in 
EU/EEA 167. In a survey among specialists from six European countries, 
restricted entitlements to hepatitis B or C treatment were reported for 
migrants in irregular situations, for asylum seekers and for persons without 
health insurance 194. Migrants in irregular situations were not entitled to ART 
for HIV in 14 of 31 EU/EEA member states in 2016 195, 196. 
In Finland, migrants living permanently in the country can be registered 
in the municipality of residence and granted entitlements to municipal 
healthcare services and national health insurance 197.  Municipalities are 
responsible for organising the infectious diseases control and providing of 
care in their area 198. Adult asylum seekers’ entitlement to care is restricted to 
necessary care whereas asylum-seeking children have no restrictions in 
entitlements to care in comparison to permanent residents 199. For migrants 
in irregular situations, entitlement to care is restricted to urgent situations 
200. HIV care during pregnancy and treatment of generally hazardous 
infectious diseases are considered urgent care 201.  Migrants in irregular 
situations pay the costs of healthcare out of pocket 202. Some municipalities 
are providing broader healthcare services for irregular migrants and 
subsidizing the treatment costs 203.  
Restricting entitlements to care has implications on health, healthcare 
systems and epidemiology of blood-borne and sexually transmitted 
infections 195. Restricted entitlements to care, such as ART for HIV, have 
been associated with increased healthcare costs 167, 204, 205. A systematic 
  
review concluded that restrictions in entitlements to hepatitis B care are 
likely to contribute to increasing infection burden in low-prevalence settings 
96.  
Table 2. Migrant-specific barriers for access to healthcare services for hepatitis B and C, 
HIV and syphilis in high-income countries 34, 142, 167, 169, 174, 193, 195, 196, 206-212. 
Availability Accessibility Acceptability
Institution ? Restricted 
entitlements to care 
due to immigration 
status
? Regulatory barriers 
in testing and care 
? Social and economic 
deprivation
? Restricted 
entitlement to health 
insurance
? Administrative 
barriers
? Policy-level 
discrimination
Healthcare 
provider
? Lack of community-
based services
? Lack of qualified 
staff 
? Lack of interpretation 
services
? Low level of 
provider-initiated 
testing
? Lack of information 
materials
? Poor referral 
pathways
? Complicated access 
to services
? Lack of culturally 
competent services
? Poor pre-test 
counselling
? Discrimination 
among health 
professionals 
Individual ? Stigma, fear of 
disease, fear of 
disclosure and 
discrimination
? Fear of impact on 
immigration process
? Differences in health 
seeking behaviour
? Availability of 
condoms
? Low acculturation
? Poor health literacy
? Poverty and 
healthcare costs
? Poor language skills
? Low perceived risk
? Fear of breaking 
patient confidentiality
 
Broadening entitlements to care does not seem to act as a pull factor for 
immigration. In Sweden, adoption of regulation on care to irregular migrants 
in 2013 did not result in increased immigration rates. Implications for the 
treatment of infectious diseases were not evaluated. 213 In Finland, impact of 
broadening entitlements to services at municipal level on the service use or 
costs has not been evaluated. 
An implementation gap between existing entitlements to care and use of 
services has been observed among irregular migrants in EU/EEA. Migrants 
with restricted entitlements to care tend to use services less than they are 
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entitled to, exemplifying other types of informal barriers in accessing care. 
174, 211, 214 
Access to care of hepatitis B and C, HIV and syphilis among migrants is 
illustrated by testing and treatment rates as well as proportion of late 
diagnoses 138. HIV testing rates among migrants from high-prevalence 
countries was 4–62% in EU/EEA with only a minority of countries reporting 
testing rates 215. In France, HIV testing among migrants was positively 
associated with lacking residency permit or unemployment suggesting that 
marginalized populations are offered testing more actively 216.  
Late diagnosis is a symptom of barriers to screening. Migrants in EU/EEA 
and other high-income regions have a higher risk for late HIV diagnosis as 
compared to natives 34, 139, 159, 217, 218. Late HIV presentation was associated 
with SSA and Southeast Asian origin in a register-based cohort in Denmark, 
and the risk remained elevated during the first year after arrival for refugees 
and up to 10 years after arrival for family-reunified migrants 159. In Finland, 
foreign nationality was associated with late HIV diagnosis and delayed access 
to care among cases notified in 1985–2005 219.  
Migrant origin has also been associated with poorer retention in care as 
compared to non-migrants. A large pan-European cohort study among 
PLWH found that migrant men especially had lower probability of ART 
initiation than native men 220. A lower proportion of migrants living with 
HIV in EU/EEA are virally suppressed in comparison to natives 46. Migrant 
PLWH in high-income countries have also a high risk for missing 
appointments and are lost-to-follow-up 34.  
A review concluded that migrants in Europe have lower CHB treatment 
initiation rates compared to residents, and findings were confirmed in a later 
cross-sectional study 221, 222. In Finland, access to HCV testing, counselling 
and treatment varies considerably in different municipalities regardless of 
residency status 223. 
2.4.3.3 Post-migration acquisition of infections 
Although infectious disease endemicity and suboptimal healthcare coverage 
including preventive services in countries of origin make an important 
contribution to migrants’ risk for infection, transmission might also take 
place post-migration either in countries of origin, transit or destination 
(Table 3). Implementation of preventive measures post-migration thus has 
the potential to prevent new infections of hepatitis B and C, HIV and syphilis 
and decrease the disease burden among migrants.  
Risk for post-migration infection of HIV in high-income countries has 
been associated with Latin American or Caribbean origin, IDU, MSM, young 
age, male sex and longer duration of residency in CCOR. Stigma, risk 
behaviours and limited access to services, among other factors, have been 
identified as reasons behind the increased risk. 34 
  
Table 3. Risk factors for transmission infectious diseases according to location and timing 
pre- or post-migration 95, 168, 169, 210, 224-226. 
Country of origin Country of residence
Pre-migration 
transmission
Transmission before migration in a 
country of origin or transit
? Higher prevalence of infections 
? Disrupted health systems and 
poor health coverage, including 
prevention and continuum of 
care
Transmission before migration in 
the current country of residence
? Poor health coverage among 
temporary migrants
? Circular migration, seasonal 
employment
? Poor health literacy
Post-migration 
transmission
Transmission post-migration in 
country of origin or transit
? Higher prevalence of infections 
? Visiting friends and relatives
? Travel-associated risk 
behaviours  
? Healthcare use during travel and 
iatrogenic transmission 
Transmission post-migration in the
current country of residence
? Poor health coverage among 
resident migrants
? Perceived lower risk and risk 
behaviours
? Assortative social and sexual 
mixing
? Poor health literacy
 
2.4.3.3.1 Post-migration acquisition rates 
An increasing body of evidence suggests that a large proportion of HIV 
infections among migrants occur post-migration, particularly in CCORs. 
Systematic review of studies published in 2002–2014 found 2–62% post-
migration acquisition rates of HIV in Europe depending on the country and 
migrant population. Post-migration transmission appeared most common 
among MSM transmissions. 95 In a recent pan-European cross-sectional 
survey among migrants living with HIV, 44.3–66.1% of the respondents 
reported a previous HIV negative test in the CCOR, with highest rates among 
MSM 209. 
A number of studies have predicted the likely date of transmission based 
on phylogenetic analyses or mathematical trajectory models 227. A 
multicentre cohort study of migrants living with HIV from nine European 
countries estimated an overall post-migration acquisition rate of 63% by 
combining self-reported background information with information on CD4-
cell counts and HIV-RNA-level measurements 227, 228. Proportion of HIV 
infections acquired post-migration was higher among MSM (72%) and PWID 
(75%) than among heterosexual men (58%) and women (51%). Migrants 
from SSA had lower post-migration acquisition rates than migrants from 
other regions. Post-migration infection with HIV was associated with longer 
time of residency and with recent diagnosis. 228 
A modelling study from France based solely on CD4 T-cell count at 
diagnosis estimated the rate of post-migration HIV infections among 
Review of the literature 
36 
migrants from SSA to be 35–49%. Risk of post-migration infections was 
associated with younger age at immigration and longer residency. 229 
Post-migration acquisition rates of HIV in Sweden based on a CD4 T-cell 
decline trajectory model were significantly higher (19%) than physicians’ 
estimates (12%). Discrepancies between physicians’ estimates and modelled 
transmission dates were associated with older patient age, higher CD4 levels, 
longer residency at diagnosis, and heterosexual transmission. 230 The rate of 
post-migration acquisition of HIV has not been evaluated among migrants in 
Finland. 
Less is known about possible post-migration acquisition of other sexually 
transmitted and blood-borne diseases. According to a systematic review and 
a meta-analysis, more than half of international migrants lack prior natural 
or induced immunity to hepatitis B 106. A register-based study from England 
and Wales indicated that the majority of South Asian migrants infected with 
acute hepatitis B had no travel history and had acquired the infection post-
migration 231.  
A phylogenetic analysis of HBV strains among Malian asylum seekers in 
Italy found that 12.5% of asylum seekers had been infected post-migration 
155. However, another study from Italy estimated the date of HBV infection 
based on phylogenetic analyses of the viral strains and compared it to the 
date of immigration, and concluded that the majority of HBV infections 
among migrants from endemic countries were acquired before immigration 
in countries of origin 232. Supporting the assumption that the majority of the 
hepatitis B and C infections among migrants are transmitted before 
migration, first-generation migrants in EU/EEA have higher HBsAg and 
HCVAb prevalence than second-generation migrants 92, 157. 
 
2.4.3.3.2 Sexual mixing 
Patterns of choosing sexual partners of similar (assortative) or different 
(disassortative) characteristics – such as origin and ethnicity – can influence 
the prevalence of infectious diseases within the sexual networks and 
subsequent risk of transmission 95, 148. Sexual mixing patterns could thus 
explain differences in epidemiological patterns between countries and 
populations 148. Phylogenetics and molecular epidemiology can be used to 
analyse the transmission networks and their dynamics 233.  
A systematic review on evidence of sexual mixing among migrants as a 
driver for post-migration HIV infections in Europe was inconclusive. 
Assortative sexual mixing was supported by the occurrence of non-B-HIV 
subtypes mainly among people born outside Europe and clustering of new 
infections by ethnicity. On the other hand, disassortative sexual mixing was 
supported by the increasing incidence of non-B-HIV clades among non-
migrants and ethnic minorities. Surveys among migrants support both 
assortative and disassortative sexual mixing. 95 
A more recent analysis of the distribution of HIV-1 sub-types in Europe 
identified introduction of non-B-subtypes of HIV-1-related to migration and 
  
later mixed occurrence of B and non-B sub-types both in migrant and native 
populations, suggesting linked epidemics and disassortative sexual mixing 37. 
Moreover, assortative sexual mixing among migrants was supported by 
findings from a pan-European collaboration study on phylogenetic clustering 
of HIV strains that found non-B strains to be present less frequently in 
phylogenetic clusters 234. 
 
2.4.3.3.3 Travel to visit friends and relatives 
Return travelling to countries of origin, or so-called visiting friends and 
relatives (VFR) tourism, is common among migrants 225, 235, 236. Travel-
related infections of food and water-borne diseases, vaccine-preventable 
diseases including hepatitis B, TB and malaria have been described among 
VFRs and studies suggest that VFRs might carry a disproportionate burden 
of travel-related morbidity 235, 237, 238.  
Longer duration of travel, travel destinations, accommodation with 
relatives, lower usage of travel health services prior to travel and increased 
risk behaviour might increase migrants’ risks for travel-related infections 224, 
225, 235-237. Sexual partnerships during travel were also common especially 
among male VFRs 225.  
Medical tourism occurs during VFR travels. Enhanced surveillance of 
hepatitis B in the UK during 1995–2000 showed that medical treatment 
during travel was the most common route of hepatitis B transmission among 
South-Asian origin migrants 231. In another study based on the Maamu 
survey, 15.4% of the Russian-origin migrants in Finland had visited a 
physician in Russia during the last 12 months 226.  
2.5 APPROACHES FOR PREVENTION 
Approaches for prevention and early diagnosis of blood-borne and sexually 
transmitted infectious diseases among migrants are mainly based on primary 
or secondary prevention strategies (Table 4). Primary prevention aims at 
averting infection 239, 240. Secondary prevention encompasses attempts to 
minimize disease-related morbidity by means of early diagnosis and effective 
treatment of those already infected. Tertiary prevention of infectious diseases 
encompasses approaches aimed at rehabilitation of the infected and 
prevention of recurrence of the disease. 239 
Primary and secondary approaches for infection prevention are 
intertwined as treating the infected can prevent further transmissions. 
Indeed, treatment of infected persons in order to reduce infectiveness and to 
prevent further transmissions has proven an attractive approach to halt 
epidemics of HCV and HIV 241. Primary prevention of HIV by short-term 
usage of ART, so-called pre-exposure prophylaxis, has been shown to be 
effective and safe 242, 243. Post-exposure prophylaxis should be offered to 
persons with a potential exposure to HIV transmission 79. 
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Table 4. Approaches for primary and secondary prevention of hepatitis B and C, HIV and 
syphilis 12, 48, 239. 
Primary prevention Secondary prevention
? Health literacy
? Vaccinations 
? Pre- and post-exposure prophylaxis
? Treatment as prevention
? Harm reduction
? Policies and strategies
? Screening
? Case finding
? Self or provider-initiated testing
? Low-threshold services
? Treatment
2.5.1 HEALTH LITERACY 
Health literacy, defined as the cognitive and social skills which determine 
individuals’ motivation and ability to access, understand and use information 
to promote health, is a key element of health promotion. Health literacy 
frameworks suggest opportunities to improve healthy behaviour by 
addressing health literacy gaps. 244 A recent systematic review concluded that 
both low knowledge and low risk-perception are likely to act as barriers to 
infectious disease prevention among migrants in the EU/EEA 193. 
Several tools have been developed to measure health literacy 245, 246. 
Following the United Nations General Assembly Special Session (UNGASS) 
Declaration of Commitment on HIV/AIDS in 2001, a specific set of 
indicators for monitoring the HIV-related knowledge, attitudes and practices 
(KAP) among young people was developed 247-249. 
Studies on health literacy among migrants and displaced populations in 
Europe indicate gaps in literacy. A cross-sectional study in Sweden on 
comprehensive health literacy among recently-arrived refugees found that 
the majority had low levels of health literacy 250. Sudanese immigrants in 
Denmark were more knowledgeable about HIV than Somali-origin migrants, 
and better knowledge was associated with male gender, older age and higher 
level of education 251. In Spain, inadequate level of HIV KAP was associated 
with North African origin and unemployment 252. Furthermore, HIV-related 
misconceptions were common among migrants in Cyprus, with better 
knowledge associated with male gender 253. In a cross-sectional study among 
migrants in Germany, knowledge on transmission routes of hepatitis B and C 
was significantly associated with younger age and higher education 254. A 
large European cross-sectional survey among migrants found that more than 
half of the respondents did not know where to access free condoms 207. 
Few studies compare STI-related health literacy between migrants and 
natives. In Germany, FSU-origin adult migrants had lower level of HIV 
knowledge compared to natives 255. Similarly in Italy, poor HIV knowledge 
was associated with migrant origin and lower level of education 256. 
  
Heath literacy has been associated with healthy behaviours such as 
condom use or STI testing rates. In a cross-sectional survey among 
immigrant Thai women in Sweden, poor knowledge of sexual and 
reproductive health (SRH) services was found to associate with low levels of 
service use 257. A systematic review found that knowledge, attitudes and 
behaviours related to HIV and healthcare services have been associated with 
HIV testing rates.  Better knowledge and engaging in HIV-related risk 
behaviours seem to increase testing whereas low perceived risk for HIV 
decreases testing. 210 Additionally, limited knowledge might hamper the 
effectiveness of strategies to reduce the burden of CHB and CHC among the 
migrant communities, as demonstrated in two qualitative study among 
migrants and general practitioners in the UK 258, 259.  
Several strategies have been adopted to improve HIV and STI-related 
health literacy among general populations 260, 261. However, recent reviews 
show a lack of documented interventions targeted to migrant populations 
including migrant MSM 34, 262-264. In the TRAIN HIV prevention programme, 
Tajik male labour migrants in transit to Russia demonstrated a significant 
increase in condom use in comparison to a control group 265. A recent review 
concluded that HIV prevention and intervention programmes might increase 
HIV testing uptake among migrants but many of the included studies did not 
measure the impact of the interventions 264. 
Effectiveness of STI prevention interventions are typically evaluated using 
indicators on sexual behaviour, such as condom use, rate of partner change 
and testing uptake as well as indicators on disease incidence and service use 
patterns 261. Health literacy interventions are more efficient in improving 
knowledge but only limited evidence exists on the effectiveness, including 
cost-effectiveness, of such strategies on improved health behaviours and 
infectious disease incidence 261, 262, 266. In fact, a Cochrane review from 2011 
concluded that although population-based interventions on STIs seem to 
have a positive influence on condom use, there was no difference observed in 
HIV incidence 267.  
Health information can be provided through various strategies and 
languages. A survey among clinicians involved in treatment of viral hepatitis 
in six European countries demonstrated a varying availability of interpreters 
and translated materials for linguistic minorities reflecting “difference-
based” and “difference-blind” approaches of service delivery to migrants and 
ethnic minorities 268. 
In Finland, municipalities have the primary responsibility of civic 
orientation and health promotion, and specific services are provided for 
migrants and refugees through a multidisciplinary approach 200, 269. For 
children and adolescents, health education is delivered mainly 
programmatically in the curriculum and in school healthcare 270. In practice, 
municipalities face challenges in reaching adult migrants through registry 
offices, municipal health and social services, immigrant service desks or 
school and student healthcare 271. Many non-governmental organizations 
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(NGOs) deliver sexual and reproductive health education for the general 
population and some also focus on foreign-origin populations 145.  
The impact of different health literacy initiatives among migrants has not 
been evaluated in Finland. National strategies and guidelines highlight that 
health education and services regarding sexual and reproductive health and 
infectious diseases should be delivered through channels that are accepted by 
and reach the at-risk populations 223, 270, 272. 
2.5.2 SCREENING 
Screening was defined by the Commission on Chronic Illness in 1951 as “the 
presumptive identification of unrecognized disease or defect by application of 
tests, examinations, or other procedures which can be applied rapidly” 240.  
Wilson and Junger suggested ten principles for screening in 1968 that were 
amended by Andermann et al. in 2008 240, 273. In short, screening should 
produce sufficient public health benefits 274.  The number needed to screen, 
defined as the number of people that need to be screened to prevent one 
death or one adverse event, can be used to compare different screening 
strategies 275. Screening tests are characterized by high sensitivity whereas 
high specificity is essential for confirmatory tests 73. 
Screening is the key approach for early diagnosis of blood-borne and 
sexually transmitted infectious diseases especially among individuals without 
a history of risk behaviours 276. These infections are often asymptomatic until 
a late stage of disease and hence only symptom-based testing can prolong the 
diagnosis. Screening of infectious diseases has a population health security 
aspect: early diagnosis limits the transmission of the disease to the 
population 277. Screening of blood-borne and sexually transmitted infections 
can be organized through universal or selective screening, or opportunistic 
testing approaches. As screening of blood-borne and sexually transmitted 
infections is based on the application of tests, the term “testing” is often used 
as a synonym for screening 240. 
Participation in screening can be mandatory or voluntary. In Finland, a 
voluntary opt-out strategy has been adopted for the majority of screening 
programmes 274. In exceptional situations, Regional State Administrative 
Agencies have the right to implement mandatory health examinations and 
screenings of generally dangerous infectious diseases as defined in the 
Communicable Diseases Act 198. 
Infectious disease screening effectiveness and cost-effectiveness are 
influenced by several factors along the screening trajectory (Figure 2). Loss-
to-follow-up might occur at every phase of the screening and care cascade, 
which compromises the effectiveness and cost-effectiveness of screening. 
Additionally, effectiveness and cost-effectiveness of infectious disease 
screening is influenced by properties of the screening test, underlying 
prevalence of infectious disease in a population and costs of treatment. 208 
  
 
Figure 2 Operational effectiveness and cost-effectiveness cascade of infectious disease 
screening and care among migrants 36, 208, 278, 279. 
2.5.2.1 Universal screening 
Universal screening refers to large-scale screening of the whole population 
without a prior selection of specific risk groups or assessment of risk factors 
for infection 240, 279. Universal strategy has several benefits: universal 
screening is usually better accepted both among patients and healthcare 
providers than screening focused only on risk groups, and it can identify 
infections among individuals with no known risk factors 280, 281. 
ECDC recommends universal HIV screening in the contexts of STI clinics 
and PWID services, ANS, cases with clinical HIV indicator conditions and in 
settings where prevalence of undiagnosed HIV is known to be high 282. 
Countries have adopted universal screening strategies for blood-borne and 
sexually transmitted infections in antenatal follow-up, prison settings, 
among high-prevalence birth cohorts or specific population groups such as 
asylum seekers 283-285.  
ANS aims to prevent MTCT by early diagnosis and treatment of the 
mother and/or the child. ECDC recommends universal opt-out HIV and 
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syphilis screening in ANS settings 280. The majority of EU/EEA countries 
have implemented ANS for CHB, HIV and syphilis, and some for rubella, 
with opt-out screening strategy being the most common approach 115. The 
Finnish ANS programme includes voluntary universal opt-out multiphasic 
screening of hepatitis B (introduced in 1994), HIV (introduced in 1998) and 
syphilis (introduced in the 1950’s) 88, 274, 286, 287. Coverage of ANS in Finland is 
approximately 98% 88. 
Several literature reviews have concluded that universal ANS of CHB, HIV 
and syphilis is effective and cost-effective 41, 279, 288, 289. Multiphasic screening 
can further reduce the costs 290. A Dutch study showed a modest cost-
effectiveness for HCV screening of first-generation non-Western migrant 
populations in the ANS context 291.  Effectiveness of ANS among migrant 
women can be compromised due to migrant-specific barriers to care such as 
poor health literacy, mistrust, stigma and fear as well as language and 
cultural differences. Scientific evidence on feasibility of different approaches 
to increase the uptake of universal ANS among vulnerable populations is 
lacking. 280 An ECDC review identified a gap of evidence on approaches to 
increase effectiveness of ANS among migrant and ethnic minority women 172. 
Blood donors in Finland are screened with universal strategy for hepatitis 
A (HAV-NAAT introduced in 2008), hepatitis B (HBsAg introduced in 1971), 
hepatitis C (HCVAb introduced in 1990, HCV-RNA in 2002), HIV 
(introduced in 1985) and human parvovirus B19 (HPVB19-NAAT introduced 
in 2001) 124, 292. Finnish best practice guidelines recommend STI testing 
among women seeking an abortion 293. 
2.5.2.2 Selective screening 
Selective, or targeted screening, encompasses screening of specific 
populations, groups or individuals at increased risk for disease 240. Selective 
infectious disease screening among migrants is implemented by the majority 
of high-income countries, especially among forced migrants, with strategies 
that differ between and even within countries 285, 294.  
Consensus on pan-European guidelines for infectious diseases screening 
among migrants has been difficult to achieve and the ECDC has emphasized 
the role of national governments in giving context-specific guidelines 11, 36, 294, 
295. Recently has ECDC published an evidence-based guideline on screening 
of key infectious disease among migrants in EU/EEA. These guidelines 
recommend screening of HBV, HCV and HIV among recently arrived 
migrants originating from countries with HBV or HCV prevalence over 2%, 
and with HIV prevalence of over 1%. In addition, HIV screening is 
recommended for all migrants at increased risk for infection. HBV screening 
should encompass both screening of infection and immunity. 36 
Twenty two of 27 of EU/EEA countries recognize migrants as a 
population vulnerable to HIV, but a smaller number of countries (16/27) 
  
recommend testing of migrants 296. One-third of EU/EEA countries have 
screening policies for CHB and CHC for migrants from endemic countries 295.  
Infectious disease screening programmes were implemented by 59% of 
EU/EEA Member States for newly arrived migrants, mainly asylum seekers 
and individuals from endemic areas, and majority had adopted a selective 
screening strategy 297. While TB was the most common disease screened 
among migrants in the EU/EEA, screening for hepatitis B was implemented 
in 33%, hepatitis C in 27%, and HIV in 27% of countries. Screening was 
mandatory in 60% of the countries performing screening. 297 Among non-EU 
countries in Europe, screening of HBV was recommended in 3/18, HCV in 
2/18, HIV in 7/18 and other STIs in 3/18 of countries 298.  
All Nordic countries recommend screening of TB among refugees and 
asylum seekers, and all except for Denmark also recommend screening of 
hepatitis B and HIV. HCV screening of refugees and asylum seekers has been 
adopted by Norway and Sweden. 299 
The effectiveness of selective infectious disease screening among migrant 
populations in Europe was assessed in a recent systematic review with 
respect to several steps along the screening pathway (Figure 2). Results 
suggest that the operational effectiveness of infectious disease screening 
programmes could be improved. Although screening uptake was high, 
coverage was suboptimal and screening and treatment drop-out rates were 
substantial. Seedat et al. concluded that the evidence for cost-effectiveness of 
screening of hepatitis B and C, and HIV among migrants from endemic 
countries was moderate and strongly linked with operational effectiveness of 
the programme and treatment costs. 208 In Germany, costs of compulsory 
infectious disease screening per capita among asylum seekers varied 
significantly depending on the content of the screening programmes, the 
price of the screening tests and the availability of follow-up services 285.  
Recently, in preparation for the ECDC guidelines on infectious disease 
screening among migrants, separate systematic reviews assessing the 
effectiveness and cost-effectiveness of HBV, CHC and HIV screening among 
migrants in the EU/EEA were published 276, 300, 301. Considering different 
elements in the screening pathway (Figure 2), evidence for effectiveness and 
cost-effectiveness of HBV screening (steps 2–4), treatment (step 7) and 
universal childhood vaccinations (step 8) were found. Selective HBV 
screening among migrant populations with CHB prevalence as low as 0.3% 
was likely to be cost-effective. 276 
Screening for hepatitis C among migrants from intermediate and high 
HCV prevalence countries in EU/EEA was found to be both effective and 
cost-effective based on evidence of test performance (step 4) and treatment 
outcomes (step 7). The systematic review identified studies demonstrating 
poor continuum of care influencing the efficacy of screening among general 
populations but no migrant population-specific information was available. 301 
An earlier systematic review of studies examining hepatitis C screening cost-
effectiveness showed a benefit for selective screening programmes among 
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high-prevalence populations such as migrants and PWID 284. A British 
modelling study found provider-initiated opt-out screening of hepatitis C 
strategy among Asian-origin migrants with an HCVAb seroprevalence of 
3.2% to be cost-effective 302. 
HIV screening was found effective with respect to universal opt-out 
screening strategy and provider-initiated testing and counselling (PITC) 
(steps 2 and 3), test accuracy (step 4), and rapid testing (step 5). Screening 
for HIV was also deemed cost-effective especially when using rapid tests, 
although no studies among migrant populations were available. 300 
Most of the cost-effectiveness studies, however, do not consider the 
benefits of multiphasic screening or model the reductions in disease burden 
achieved with treatment and vaccinations 41, 303. Neither did the studies 
assess cost-effectiveness in relation to migration status 41, 278. Additionally 
migrants might have specific vulnerabilities to interrupted care and loss-to-
follow-up, which influences disease progression and cost-effectiveness of 
treatment in comparison to general populations 41, 222.  
Some studies have questioned acceptability of selective screening in 
comparison to universal strategies. Reluctance towards ethnic targeting of 
selective screening among migrants has been observed as a barrier for HBV 
and HIV testing in mixed methods studies from the UK 304-306. 
In Finland, national guidelines on selective screening of blood-borne and 
sexually transmitted infections among migrants have been available since the 
1980s 272, 307-310 (Table 5). Screening is offered for asylum seekers and 
refugees after arrival based on an individual risk assessment considering 
infection endemicity in the country of origin (TB incidence > 50 per 100,000, 
CHB prevalence > 2%, HIV prevalence among adults > 1%), arrival from 
conflict zones or refugee camps, family members or close contacts diagnosed 
with infectious diseases, and other risk factors related to personal medical 
history or risk behaviours 272, 311. Screening for pulmonary TB is 
recommended for migrants from countries with TB incidence over 150 per 
100,000 and for certain employees 312-314. 
2.5.2.3 Case finding 
In a broad sense, case finding refers to any attempts to identify infected 
among those at risk to bring them to treatment, and encompasses different 
screening approaches 240. In communicable disease control practice, case 
finding generally refers to disease outbreak management. Case finding 
through partner notification enables informing, screening and treatment of 
close contacts of an infected 81. 
 
 
 
  
Table 5. Guidelines on screening of infectious diseases among migrants, refugees and 
asylum seekers in Finland.
Guideline Target group Approach Targeted infection(s): test
Medical board 
1980 309
Refugees and 
adopted children
Universal Refugees:
? Hepatitis B: HBsAg
Adopted children:
? Hepatitis B: ALAT and ASAT, if 
elevated HBsAg
? Syphilis: Cardiolipin
Medical board 
1990 310
Refugees and 
asylum seekers
Universal ? Hepatitis B: HBs-Ag
? HIV: HIV-Ab
? Syphilis: Cardiolipin (VRDL)
? Pulmonary tuberculosis: Chest X-ray
Ministry for 
Social Affairs 
and Health 
1993 308
Refugees and 
asylum seekers
Selective 
multiphasic, 
voluntary
? Hepatitis B: HBs-Ag
? HIV: HIV-Ab
? Syphilis: Cardiolipin (VRDL)
? Intestinal parasites for children under 
7 years of age 
? Pulmonary tuberculosis for all above 
7-years of age: Chest X-ray 
? Latent tuberculosis for unvaccinated 
children under 7-years of age: 
Mantoux
Ministry for 
Social Affairs 
and Health 
2009 272
Refugees and 
asylum seekers
Selective 
multiphasic, 
voluntary
? Hepatitis B: HBsAg
? HIV: HIVAgAb
? Syphilis: TrpaAb if either HBsAg or 
HIVAgAb test is taken
? Intestinal parasites for children under 
16 years of age: Stool cyst 
microscopy
? Pulmonary tuberculosis: Chest X-ray
? Latent tuberculosis for unvaccinated 
children under 7-years of age: IGRA 
or Mantoux
Ministry for 
Social Affairs 
and Health 
2014 312
Migrants from 
high tuberculosis 
incidence 
countries
Selective, 
voluntary
? Pulmonary tuberculosis: Chest X-ray
National 
Institute for 
Health and 
Welfare 2017 
313
Migrants from 
very high 
tuberculosis 
incidence 
countries
Selective, 
voluntary
? Pulmonary tuberculosis: Chest X-ray
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A systematic review and a meta-analysis concluded that assisted partner 
notification is more effective in increasing screening uptake among partners 
and identifying HIV-infected partners in comparison to passive referral. No 
studies on migrant populations were included in the review. 315 WHO 
recommends the implementation of voluntary assisted partner notification 
services for HIV 316. A qualitative study among Somali-origin migrants in the 
UK found partner notification acceptable also in the context of HBV 306. 
In Finland, the Communicable Diseases Act deems case finding and 
partner notification of patients with generally hazardous (syphilis) or 
notifiable communicable diseases (hepatitis B and C, HIV) mandatory 198. 
However, contact tracing should primarily be performed in mutual 
understanding and collaboration with the index case 317. 
2.5.2.4 Opportunistic screening 
Opportunistic screening, as opposed to systematic or organized screening, 
occurs non-systematically and can be provider or self-initiated. 
Opportunistic screening complements systematic screening programmes and 
can influence their cost-effectiveness 274. 
 
2.5.2.4.1 Provider-initiated opportunistic screening 
PITC relies on provider’s awareness of the possibilities of offering testing and 
secondly, on acceptability of testing 145, 270, 281. PITC can encompass the offer 
of information on transmission, prevention and the significance of either 
test-negative or test-positive result 317. Culturally sensitive PITC is effective 
but relatively costly intervention to increase test uptake among migrant 
populations 142, 264. Peer-led approaches and bundling of PITC can also be 
effective 34. 
In situations of concentrated or low-level HIV epidemics, WHO 
recommends indicator condition guided PITC. PITC should also be offered in 
STI services, services for most-at-risk populations, in ANS and 
accompanying treatment of TB. 318 
Finnish national HIV testing guidelines recommend PITC for persons 
with symptoms related to primary HIV infection or diagnosis of any AIDS-
defining illness, other blood-borne or sexually transmitted infection, 
presenting with immunocompromised situation, or vulnerabilities for HIV 
infection. PITC should also be offered to persons vulnerable to HIV: migrants 
from high HIV prevalence countries, travellers to HIV-endemic areas, 
partners of HIV-positive individuals, sex workers and PWID. 145, 317 HCVAb 
test is recommended for newborns of HCVAb-positive mothers, PLWH, and 
persons at-risk of HCV through IDU or other unsafe injections, surgical 
operations or blood transfusions 223.  
Opportunities of PITC exist at every healthcare contact. There is 
conflicting evidence on the use of healthcare services among migrants. A 
  
recent systematic review concluded that migrant children appear to use less 
health services in comparison to non-migrants 319. On the other hand, 
migrants in the EU/EEA use more emergency department services in 
comparison to native populations 320. 
Several factors influence providers’ awareness of the opportunities to 
offer testing such as history of immigration from a high-prevalence country 
or precarious socio-demographic determinants 94, 216. Restricted access to 
public healthcare services direct migrants to migrant-sensitive services where 
healthcare professionals might be more ready to offer testing 321. In France, 
migrant men in irregular situations had a higher probability of previous HIV 
testing in comparison to employed men with residency permits 216. However, 
a recent mixed-methods systematic review demonstrated that migrants from 
high HIV prevalence countries were not frequently tested for HIV in primary 
care mainly due to providers’ perceived barriers to offer testing including 
language barriers, perceived lack of competence in culturally sensitive sexual 
counselling as well as awareness of migrants’ restricted entitlements to care 
281.  
According to a recent pan-European survey among migrants, 87% of the 
participants had accessed healthcare in the CCOR during the last 12 months 
and half of those who had visited healthcare reported that HIV testing was 
mentioned during the visit 207. Similarly, 70.7–83.0% of HIV-positive 
migrants in Europe had attended health services within two years prior to 
diagnosis but only 24.8–38.9% recalled an offer of HIV test 209.  
Although general practitioner was the most common health service visited 
after immigration, the majority of HIV diagnoses among migrants living with 
HIV in Europe were made in secondary or tertiary care, and among MSM in 
sexual health clinics 207, 209. In a French study among migrants in Paris 
region, first-time HIV test after arrival occurred due to physician’s request 
for 27.7% of migrant men and for 23.7% of migrant women visiting primary 
healthcare 216. Finnish national HIV strategy emphasizes the role of primary 
care and low-threshold services in PITC 145. 
Acceptability of PITC differs according to the testing settings, 
methodology, costs and patient populations. A review on HIV testing uptake 
among migrants and ethnic minorities showed 23–64% acceptability of PITC 
in studies conducted in Europe 142. A high acceptability (91.4%) of 
multiphasic provider-initiated point-of-care CHB/HCVAb/HIVAb/syphilis 
testing was achieved among migrants in irregular situations visiting a free-of-
charge migrant-sensitive health service in Northern Italy 322. Uptake of an 
opt-out multiphasic HIV/HBV/HCV test at UK emergency departments was 
positively associated with migrant and ethnic origin even though only a 
modest acceptability of 39% was achieved 323. Multiphasic screening of 
HIV/HBV/syphilis/stool parasitic infections offered for recently arrived 
asylum seekers at refugee shelters in Italy was accepted by 96% 324. A 
qualitative study among migrants and healthcare providers in Spain found 
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that PITC is conceptually acceptable for both the service users and providers 
325. 
 
2.5.2.4.2 Self-initiated testing 
Self-initiated testing is an important asset especially for reaching those not 
enrolled in screening programmes or visiting healthcare services. Self-
initiated testing is increased by improving the availability and variety of 
innovative testing approaches, such as point-of-care rapid diagnostic tests, 
community testing, home-based sampling as well as self-testing 138, 142, 326.  
In a French study among migrants, first HIV testing after migration was 
self-initiated among 25.9% of migrant men and 15.4% of migrant women 
visiting primary healthcare 216. According to Finnish national guidelines, self-
initiated HIV testing should be available without a physician’s referral, 
anonymously and free-of-charge 317. Access to self-initiated testing has not 
been evaluated at the national level. 
WHO recommends HIV self-testing as an additional approach to increase 
the coverage of self-initiated HIV testing 316. Many EU/EEA countries have 
developed or are planning to develop policies to support HIV self-testing 211, 
327. HIV self-testing became available in Finland in August 2018 328.  
Evidence on the acceptability and performance of self-sampling 
technologies among migrant populations is scarce 304, 305. In a Dutch migrant 
population-based study, 1.4% of migrants had self-tested for HIV/STIs 
during the last 12 months and testing was associated with African origin, 
higher number of lifetime sexual partners and having had a condomless 
intercourse with a casual partner during the last six months 329. In another 
cross-sectional study among migrants in France, the Netherlands and the 
UK, 1.9% of participants had self-tested for HIV during the last 12 months 
330. 
 
2.5.2.4.3 Low-threshold services 
Low-threshold services aim at lowering barriers for counselling, testing, 
diagnosis and treatment of blood-borne and sexually transmitted infections, 
and usually take place in communities outside traditional healthcare settings. 
Community-based awareness raising and testing services benefit from 
tailored, culturally sensitive approaches and have strong acceptability in the 
communities 208. In settings with concentrated epidemics, low-threshold 
services can target key populations for prevention such as MSM, PWID, sex 
workers, adolescents, migrants and mobile workers 132.  
WHO recommends community-based HIV testing and counselling 
services as an effective approach to increase HIV testing uptake 132. In 
EU/EEA, community-based point-of-care HIV and HBV/HCV testing 
performed by non-medical staff has been implemented in one-third of the 
countries 138, 295. A third of EU/EEA countries identify gaps in HIV 
prevention services for migrants and a half recognize stigma and 
discrimination limit the uptake of HIV prevention services 196. 
  
Community-based non-clinical low-threshold services can reach good 
screening uptake among migrant populations 208. A recent systematic review 
concluded that voluntary counselling and rapid testing for HIV among 
migrants was associated with an increase in HIV-testing uptake and receipt 
of results in comparison to conventional testing 300. 
Enhanced HIV surveillance in UK demonstrated that ethnicity was 
associated with using community low-threshold services as opposed to 
specialist clinics or units within the public health system 331. Attendance to 
community clinics was highest among the most vulnerable migrant 
populations: refugees, temporal workers and migrants in irregular situations 
331. Community outreach activities might also be beneficial in improving ANS 
coverage among migrant women 280.  
Governments facing economic hardship and austerity measures, NGOs in 
Europe have become more prominent in providing preventive measures, 
testing and healthcare for migrants 10, 145. Organizations’ services are 
characterized by easy access, holistic approach, adaptable multidisciplinary 
services and confidentiality 332.  
In Finland, NGOs have long traditions of providing community-based 
counselling and testing services for migrant sub-groups in various languages. 
Low-threshold counselling, substitution treatment, and syringe and needle 
exchange services for PWID in Finland have been found to be effective in 
preventing transmission of blood-borne infectious diseases 333, 334. Substance 
abuse services and testing for migrants is provided by a network of 
community-based A-clinics (www.addictionlink.fi). The Global Clinic 
provides services including STI testing for migrants in irregular situations 
(www.globalclinic.fi). Hivpoint offers information, counselling and point-of-
care HIV/HCV testing targeting especially migrants, MSM and travellers 
(www.hivpoint.fi). Pro-tukipiste offers support, health and social services for 
persons working in sex and erotic industry (www.pro-tukipiste.fi). 
2.5.3 VACCINATIONS 
HBV and HPV are currently the only blood-borne and sexually transmitted 
infections that can be prevented with vaccinations. WHO recommends 
immunization of all infants against hepatitis B as primary prevention. First 
dose of the HBV vaccine should be provided within 24 hours from birth. In 
addition to adopting universal childhood HBV immunization programme, 
WHO supports targeted catch-up HBV vaccinations among at-risk 
populations. 55  
Migrants in Europe have lower immunization rates and are vulnerable to 
vaccine-preventable diseases including hepatitis B 212, 335. Migrants face 
specific barriers to vaccinations but evidence on effective interventions to 
address these barriers remains limited (Table 2) 212. 
In a systematic review and a meta-analysis, seroprevalence of overall 
immunity to HBV (HBsAb seropositivity) was 39.7% among migrants from 
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intermediate and high-prevalence areas, and highest among migrants from 
areas with high CHB prevalence 106. Recent cross-sectional studies among 
asylum seekers in Europe have found that 5.6–29.3% of study subjects have 
vaccine-derived immunity to hepatitis B (HBsAb seropositive with HBsAg 
and HBcAb seronegative) 294, 324, 336-339. HBV immunity through vaccination 
was significantly higher among children and among migrants from the 
Eastern-Mediterranean region as compared to older age groups and other 
regions of origin 294. Furthermore, evidence of current or spontaneously 
resolved infection (HBcAb seropositivity) was found among 12.8–62.2% of 
the asylum seekers 150, 294, 324, 336, 340-343. 
The majority of countries in Europe have included universal HBV vaccine 
in the national vaccination programmes. Some, including Finland, have 
opted for targeted vaccination strategies. 344, 345 Finland has implemented 
targeted vaccination of at-risk populations since 1993, as cost-effectiveness 
studies to-date have not supported inclusion of universal hepatitis B 
vaccinations in the national vaccination programme 57, 346, 347. Free-of-charge 
hepatitis B vaccine is offered for newborns of HBsAg or HCVAb-positive 
mothers, family members and partners of HBsAg-positive individuals and for 
newborns whose either parent originates from countries with HBV 
endemicity over 2%. Additionally, HBV vaccinations target PWID and their 
family, commercial sex workers, MSM, haemophilia patients and certain 
employees as well as victims of needle stick injuries. 348 All permanent 
residents and asylum-seeking children in Finland are entitled to vaccinations 
according to the national vaccinations programme 349. Asylum-seeking adults 
are entitled only to necessary vaccinations 199. Implementation and coverage 
of the hepatitis B vaccination programme among at-risk-populations has not 
been evaluated. 
2.5.4 PUBLIC POLICIES 
Public policies shape the national, regional and global public health 
responses to infectious disease epidemics. The key global actors in migrant 
health include the United Nations (UN) and the World Health Organization 
(WHO). The work of the UN is coordinated through several programmes 
such as the joint UN Programme on HIV/AIDS (UNAIDS), UN Migration 
Agency (International Organization for Migration, IOM), UN Refugee Agency 
(UNHCR) and the International Labour Organization (ILO). International 
human rights conventions recognize a universal human right to health 
regardless of residency status 350-352. Specific rights of refugees were 
recognized in 1951 16, 353. 
UN adopted the 2030 agenda for Sustainable Development in a General 
Assembly held in October 2015 with 17 Sustainable Development Goals 
(SDGs), 169 associated targets and 232 indicators for development 354, 355. 
Migrants, youth and PLWH are recognized as vulnerable populations in the 
  
agenda. Target 3.3 calls for ending the HIV epidemic by 2030 and combating 
hepatitis and other infectious diseases 354. HBV and HIV incidences by sex, 
age and among key populations have been included as indicators of progress 
towards target 3.3 355. ART coverage and International Health Regulations 
(IHR) core capacity index are included as indicators for the monitoring of 
achievement of universal health coverage (SDG3.8) 356. SDG3 “Good health 
and wellbeing” is a key component of Finland’s national implementation plan 
of the 2030 agenda 357, 358.  
Following accelerating societal discussion on migration and the European 
migrant crisis in 2015, the UN general assembly adopted the New York 
Declaration for Refugees and Migrants in September 2016 359. The New York 
Declaration calls for global multisector collaboration in order to ensure the 
human rights for migrants and refugees, address the root causes of forced 
migration and strengthen safe and orderly migration routes, and started the 
process of development of the Global Compact for Safe, Orderly and Regular 
Migration coordinated by the IOM. Resolution on the Global Compact on 
Migration was adopted by the UN general assembly in December 2018 and is 
expected to bring fresh approaches to migration governance 360. WHO is 
actively promoting the inclusion of migrant health as a prerequisite for 
development in the compact’s agenda, especially focusing on enhancing 
health monitoring among migrants and ensuring universal health coverage 
361. 
International Health Regulations (IHR) have been adopted and ratified by 
all WHO member states, including Finland. The IHR aims to strengthen the 
global efforts to prevent and control cross-border health threats such as 
infectious diseases 362. Migration and mobility are not specifically mentioned 
in the IHR, although large influx of migrants could constitute a public health 
emergency of international concern. Implementation of the IHR is 
monitored through a self- and peer-evaluation system, and reported to the 
World Health Assembly annually 363, 364. Joint External Evaluation of IHR 
Core Capacities in Finland in 2017 recommended ensuring vaccination 
coverage especially among asylum seekers and migrants in irregular 
situations 365. 
WHO’s Global Health sector strategies on viral hepatitis and HIV 2016-
2021 contribute to the achievement of the SDGs 366, 367. The strategic 
approaches to achieve the elimination of viral hepatitis include vaccinations, 
prevention of MTCT, stopping iatrogenic infections, harm reduction, and 
treatment 366. For HIV, the key strategic interventions include enhancing 
prevention through new biomedical tools, adoption of the “90-90-90” target, 
and focusing on hard-to-reach populations including mobile populations 367. 
The 90-90-90 target by UNAIDS aims at improved continuum of HIV care by 
(1) achieving diagnosis of 90% of all HIV-infected people; (2) establishing 
ART for 90% of PLWH; and (3) sustaining viral suppression among 90% of 
those on ART 368. Migrants are mentioned as a key population potentially 
vulnerable and at-risk for viral hepatitis and HIV 366, 367. UNAIDS strategy for 
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2016–2021 and the “90-90-90” target urge for broadening options for 
screening in communities, at home and innovative public-private 
partnerships 368, 369. The Global Vaccine Action Plan 2011–2020 also urges 
approaches to reach especially urban migrants for vaccinations 370.  
In Europe, migrant women especially suffer exclusion and ill-health due 
to several overlapping vulnerabilities, including infectious diseases, and the 
European health policy framework suggests addressing these issues by 
combatting social exclusion processes 371. The Dublin Declaration on 
Partnership to Fight HIV/AIDS in Europe and Central Asia in 2004 enforced 
the collaboration between WHO Regional Office for Europe and ECDC for 
the control and monitoring of the HIV epidemic also among migrants and 
mobile populations in the area 372. In the context of concentrated HIV/AIDS 
epidemic, the European Action Plan for HIV/AIDS acknowledges the need to 
develop targeted approaches to reach key population at high risk such as 
migrants, and to ensure universal access to testing and care, and also 
supports the removal of mandatory HIV testing based on migration status 
373. The strategy and action plan for refugee and migrant health in Europe 
calls for ensuring coordination, enhanced surveillance and migrant-sensitive 
interventions to control infectious disease threats 374. 
In Finland, the national hepatitis C, HIV and SRH strategies acknowledge 
migrants as key population for public health action 145, 223, 270. National 
hepatitis C strategy 2017–2019 supports HCV screening after arrival among 
asylum seekers from high-prevalence settings 223. Key strategic approaches to 
HIV among migrants include enhancing health literacy, early diagnosis 
through migrant-sensitive services and preventing post-migration infections. 
Universal access to testing and treatment should be ensured for all migrant 
populations. 145 
2.6 SUMMARY OF THE LITERATURE REVIEW AND 
GAPS IN KNOWLEDGE 
Trends in international migration and mobility are likely to persist resulting 
in increasingly diverse societies that will require health systems to adapt. 
Migrants are vulnerable to sexually transmitted and blood-borne diseases 
including hepatitis B and C, HIV and syphilis, and have a disproportionately 
high disease burden in low-prevalence countries, such as Finland.  
The epidemiology of hepatitis B and C, HIV and syphilis among migrants 
mirrors the prevalence of infections in the countries of origin, although 
selective migration is likely to explain the somewhat lower risk for infection 
among those who decide to migrate as compared to those who decide to stay. 
A proportion of infections occurs post-migration as a result of specific 
vulnerabilities to infections related to health literacy, health service coverage 
and behavioural factors. While several strategies have been adopted to 
  
address these vulnerabilities, their implementation and effectiveness have 
rarely been evaluated.  
Epidemiology of infectious diseases among migrants is specific to time, 
place and population. In order to address the gaps in public health response 
to hepatitis B and C, HIV and syphilis among migrants, evidence is needed 
on the infection prevalence, population groups at increased risk, health 
seeking behaviours and effectiveness of the current approaches. 
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3 AIMS OF THE STUDY 
The aims of the study are 
 
1. to assess the feasibility of infectious disease screening in a migrant 
population health survey context with respect to participation and 
acceptability of screening (publications I and II) 
 
2. to estimate the burden of hepatitis B and C, HIV, and syphilis among 
different migrant populations in Finland (publications I and III) 
 
3. to evaluate the implementation and coverage of infectious disease 
screening among different migrant populations in Finland (publications I, 
III and IV) 
 
4. to describe HIV-related knowledge, attitudes and practices of young adult 
asylum seekers (publication IV). 
  
4 MATERIALS AND METHODS 
4.1 STUDY POPULATIONS 
4.1.1 MIGRANTS WITH LONG-TERM RESIDENCY (I, II)
EU nationals or nationals to third countries who have a residency permit to 
Finland, and have lived or have the intention to live in Finland for a 
minimum of one year can be registered in the population information system 
(PIS) with a municipality of residence. After registration persons have full 
access to public health services, including prevention and treatment of 
infectious diseases. 197 Emigration data in the PIS is based on personal 
notifications and register corrections 375. 
The largest resident migrant populations in Finland in 2010 were persons 
born in FSU or Russia, Estonia, Iraq or Iran, and Somalia, in descending 
order, representing 38% of the total migrant population in 2010 30. Majority 
of migrants from Iraq, Iran and Somalia have received residency through 
refugee status whereas migrants from FSU and Russia have immigrated due 
to study, work or family ties 376. 
Publications I and II used data from the Maamu survey which included 
three of the largest resident migrant populations in Finland in 2010. 
Inclusion criteria for the Maamu survey were: (1) Kurdish, Russian or Somali 
origin; (2) 18 to 64 years of age; (3) having lived in Finland for at least one 
year; and (4) living in Espoo, Helsinki, Vantaa, Tampere, Turku or Vaasa 
cities. Kurdish origin was defined as being born in Iran or Iraq and speaking 
Kurdish as mother tongue. Russian origin was defined as being born in 
Russia or FSU and speaking Russian or Finnish as mother tongue. Somali 
origin was defined as being born in Somalia. No participants were excluded. 
376 
Publication I included all individuals invited to participate in the Maamu 
survey and who had immigrated to Finland after January 1, 1995. The 
immigration year was limited in order to ensure that if an individual had 
been diagnosed with a notifiable infectious disease, the notification was 
registered in the National Infectious Disease Register (NIDR). 
Publication II included participants in the Maamu pilot and Maamu 
surveys who lived in Helsinki. 
4.1.2 ASYLUM SEEKERS (III, IV) 
Asylum seekers are migrants seeking for international protection in a foreign 
country. While waiting for a decision on the residency permit application 
based on refugee status, asylum seekers are not considered permanent 
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residents in Finland and are not registered in the PIS. 13 Once receiving a 
residency permit, asylum seekers are registered in the PIS and assigned a 
municipality of residence. The Finnish Immigration Service is responsible of 
the processing of the asylum applications and organization of services, 
including healthcare services, for asylum seekers. Finnish Immigration 
Service also maintains register on asylum applications. 199 
Publication III included all asylum seekers who applied for asylum in 
Finland in 2015–2016. Persons with unknown or with no nationality were 
excluded. 
Publication IV included participants in the TIE survey aged 20 to 25 
years. Inclusion criteria for the TIE survey were (1) having asylum 
application in process; (2) 16 to 25 years of age; (3) originating from Middle 
East and North Africa 377, the FSU countries or SSA 377; and (4) living in one 
of the three selected reception centres in Finland: Pansio reception centre in 
Turku, or Kaarlenkatu or Punavuori reception centres in Helsinki. No 
participants were excluded. 
4.1.3 GENERAL POPULATION YOUNG ADULTS (IV) 
General population young adults were chosen as a control group. Young 
adults of 20–25 years of age represented 6% of the Finnish population in 
2014 30. Children and young people are considered as a key population for 
SRH promotion in Finland. Often multiple important life changes occur in 
young adulthood such as engaging in first longer intimate relationships and 
young adulthood can involve increased risk behaviours for blood borne and 
sexually transmitted infections. 270  
Publication IV included participants in the World Aids Day survey in 2014 
(WAD 2014) aged 20 to 25 years. The inclusion criteria for the WAD 2014 
survey were (1) 20 to 29 years of age and (2) having electronic contact 
information in the Taloustutkimus Ltd.’s register. No participants were 
excluded. 
4.2 RESEARCH QUESTIONS 
Research questions relevant for each study aim are summarized in Table 6. 
PICOT approach was used to frame the research questions according to 
population of interest (P), issue or intervention (I), comparison (C), outcome 
(O), time and setting (T) 378. 
 
 
 
 
 
 
  
Table 6. Summary of research questions based on the PICOT framework 378.
Study aim Research question (PICOT) Publication
Feasibility of 
screening
Did the notification prevalence of hepatitis B, hepatitis C, HIV 
and syphilis (O) differ among participants (P) and non-
participants (C) in the Maamu survey (T)?
I
What was the acceptability (O) of HBsAg, HCVAb, HIVAgAb
and TrpaAb screening (I) among migrants who immigrated 
after 1995 (P, C) in the Maamu survey (T)?
I
What factors were associated with the acceptability (O) of 
HIVAgAb test (I) among adult migrants resident in Helsinki 
(P, C) in the Maamu survey and Maamu survey pilot (T)?
II
Seroprevalence What was the seroprevalence (O) of HBsAg, HCVAb,
HIVAgAb, and TrpaAb among migrants who immigrated after 
1995 (P) who were screened (I) in the Maamu survey (T)?
I
What was the seroprevalence (O) of HBsAg, HIVAgAb and 
TrpaAb among asylum seekers (P) who were screened (I) in 
Finland during 2015–2016 (T)?
III
Implementation 
of screening
What was the self-reported coverage (O) of infectious 
disease screening (I) among migrants immigrated after 
1995(P) in the Maamu survey (T)? 
I
What was the coverage (O) of HBsAg, HIVAgAb and TrpaAb
screening (I) among asylum seekers (P) in Finland during 
2015–2016 (T)?
III
What was the self-reported coverage (O) of HIV screening (I) 
among asylum seekers (P) in comparison to the general 
population (C) in the TIE and WAD 2014 surveys (T)?
IV
What was the delay (O) from immigration to hepatitis B or C,
HIV or syphilis notification (I) among migrants who
immigrated after 1995 (P) in the Maamu survey (T)?
I
What was the delay (O) from immigration to HBsAg, 
HIVAgAb and TrpaAb screening (I) among asylum seekers 
(P) in Finland during 2015–2016 (T)?
III
Knowledge, 
attitudes and 
practices
How did the HIV-related knowledge, attitudes and practices 
(O) among young adult asylum seekers (P) differ as 
compared to general population (C) in TIE and WAD 2014 
surveys (T)?
IV
PICOT framework = Population (P), Issue or intervention (I), C (Comparison), Outcome (O) 
and Type of study (T). Maamu = Migrant Health and Wellbeing Survey. TIE = TIE survey. WAD 
2014 = World Aids Day survey in 2014.
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4.3 SURVEYS 
4.3.1 MIGRANT HEALTH AND WELLBEING SURVEY AND PILOT 
SURVEY 
Maamu survey was a cross-sectional observational population-based health 
interview and examination survey among adult Kurdish, Russian and 
Somali-origin migrants in Finland during 2010–2012. Simple random 
sampling stratified by origin and place of residency was performed from the 
PIS in 2010. In total 3,000 migrants – 1,000 from each origin – were invited 
to participate in the survey. 376 
Participation in the Maamu survey was voluntary and participants 
provided a written informed consent for the health interview, examination 
and laboratory tests separately. Participants’ travel expenses to the survey 
location by public transport were covered and they were given a small 
voucher to a local cafeteria as remuneration for their participation. 376 
Health interviews and examinations in the Maamu survey were 
performed by nurses speaking Finnish, Kurdish Soran, Russian or Somali. 
The health interview included questions on socio-demographic background, 
health service use and previous medical history including TB. In addition to 
the standard interview protocol, a short protocol including only the most 
essential questions was developed in order to increase the participation for 
the survey. 376 
Current symptoms of active pulmonary TB, HIV-related knowledge, 
participation in previous HIV testing and history of blood-borne infections 
were surveyed during the health examination. HIV KAP was assessed using 
the UNGASS indicator questions including an additional question on the 
prognosis of HIV under treatment 248. 
All participants in the health examination were offered screening for 
HBV, HCV, HIV and syphilis. Blood samples were drawn in a laboratory after 
receiving the written consent. Screening tests and the confirmatory tests, 
apart from confirmatory HCV tests, were performed in the ANS laboratory of 
the National Institute for Health and Welfare. HCVAb-positive test results 
were confirmed by HUSLAB, the laboratory of Helsinki University Central 
Hospital and the Hospital District of Helsinki and Uusimaa. All screening 
tests had over 98% specificity and sensitivity 88, 379-387 (Table 7). Samples 
positive for Treponema-specific antibodies were further analysed with Rapid 
Plasma Reagin to assess the infection activity 85, 88.  
Before beginning of the official data collection, Maamu survey was piloted 
in Helsinki in 2010 to test the health interview and examination protocol. 
Fifty participants from each migrant population were randomly selected 
from the PIS. Then inclusion criteria for the pilot were the same as for the 
Maamu survey except that the city of residency was limited to Helsinki. 376 
 
  
Table 7. Screening tests used in Maamu survey and in screening of the asylum seekers. 
Infection Primary test Confirmatory test
Hepatitis B ARCHITECT® HBsAg Qualitative 
(Abbot, Chicago, Illinois, USA) 380
? Purpose: HBsAg detection
? Method: Chemiluminence 
microparticle immunoassay
AXSYM® Confirmatory (Abbot, 
Chicago, Illinois, USA)a 381
? Purpose: HBsAg detection
? Method: Microparticle enzyme 
Immunoassay
Hepatitis Ca ARCHITECT® Anti-HCV (Abbot, 
Chicago, Illinois, USA) 382
? Purpose: HCVAb detection
? Method: Chemiluminence 
microparticle immunoassay
INNOTEST® HCV Ab (Fujirebio, 
Malvern, Pennsylvania, USA) 383
? Purpose: HCVAb detection
? Method: Enzyme Immunoassay
HIV ARCHITECT® HIV Ag/Ab Combo 
(Abbot, Chicago, Illinois, USA) 384
? Purpose: Detection of HIV p24 
antigen and antibodies to HIV-1
and HIV-2
? Method: Chemiluminence 
microparticle immunoassay
INNO-LIA® HIV (Fujirebio, Malvern, 
Pennsylvania, USA) 385
? Purpose: Detection and 
differentiation of antibodies to HIV-
1 and HIV-2
? Method: Line immunoassay 
Syphilis ARCHITECT® Syphilis TP (Abbot, 
Chicago, Illinois, USA) 386
? Purpose: Detection of antibodies 
to Treponema pallidum
? Method: Chemiluminence 
microparticle immunoassay
IMMULITE® 2000 Syphilis (Siemens, 
Munich, Germany)b 379
? Purpose: Detection of antibodies 
to Treponema pallidum
? Method: Quantitative 
immunoassay
INNO-LIA® Syphilis (Fujirebio, 
Malvern, Pennsylvania, USA)a 387
? Purpose: Detection of antibodies 
to Treponema pallidum
? Method: Line immunoassay
aUsed only in Maamu survey; bUsed only in screening of the asylum seekers.
 
Based on experience from the pilot, small changes to the survey protocol 
were made, including enhancement of the pre-test counselling for HIV in 
order to motivate participation in the HIV testing. Enhanced pre-test 
counselling included normalization of testing as well as explaining the 
benefits of testing for the community and for purposes of the survey. 376 
Factors influencing the acceptability of HIV testing, such as enhanced 
counselling among others, were assessed (II). 
Migrants who had accepted testing in Maamu survey were considered 
participants and the rest as non-participants. Notifications of hepatitis B and 
C, HIV and syphilis in the NIDR during January 1, 1995 and December 31, 
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2009 were compared between participants and non-participants in the 
survey to assess non-participation (I).  
Among those who accepted testing, the proportion and risk factors for any 
missed diagnosis were assessed (I). Missed diagnosis was defined as a test-
positive case in Maamu survey without a prior notification in NIDR. Delay 
from immigration to notification was calculated by comparing the 
immigration and notification dates. Delays were grouped into three 
categories: (1) notification within one year of immigration; (2) notification 
after one year post-immigration but prior to Maamu survey; and lastly (3) 
diagnosis at Maamu survey. 
4.3.2 TIE SURVEY 
The TIE survey was conducted as a part of project for prevention and early 
diagnosis of HIV and TB among young asylum seekers in Finland. The 
project took place during 2012–2015 and was coordinated by the Finnish 
Lung Health Association and received funding from the European Refugee 
Fund 388, 389. 
TIE survey was a cross-sectional observational health survey on HIV and 
TB-related KAP among young adult asylum seekers in Finland in 2014. The 
participants were recruited by convenience sampling by nurses working in 
the reception centres. Participation was voluntary and a written informed 
consent was obtained from the participants. 388, 389 
Participants filled in an anonymous written 50-item structural 
questionnaire in Arabic, English, Russian, Somali or Soran. The 
questionnaire included items on socio-demographic background and HIV 
and TB-related KAP. 389 HIV knowledge was assessed using the UNGASS 
indicator questions developed for monitoring of the global HIV response 
(Table 8) 390. An additional question about the knowledge of the availability 
of medication to treat HIV was posed. HIV related attitudes were surveyed by 
assessing attitudes towards PLWH. HIV related practices were evaluated by 
assessing the proportion previously tested for HIV. 
Questionnaires were filled in a classroom setting and interpreters helped 
those with reading difficulties. All questions had either a Likert scale or an “I 
don’t know” option. Answering all questions was not obligatory. The 
reception centre nurse and the survey doctor were present to answer possible 
questions. After completion of the survey, participants received a chocolate 
bar as a token. 389 
4.3.3 WORLD AIDS DAY SURVEY 
WAD surveys have been performed for several years among different target 
groups and the results are typically published on the World Aids Day on the 
December 1. The focus of the surveys has been at HIV-related KAP. WAD 
  
surveys have been designed and coordinated by a network of NGOs and 
patient organisations working with HIV in Finland. 
Table 8. UNGASS core indicator for monitoring young people’s knowledge about HIV 
prevention; 2002 version and 2010 update 248, 249. 
No. Question Correct 
answer
UNGASS1 2002: Can the risk of HIV transmission be reduced by having sex with 
only one faithful, uninfected partner?a
Yes
2010: Can the risk of HIV transmission be reduced by having sex with 
only one uninfected partner who has no other partners?
UNGASS2 2002: Can the risk of HIV transmission be reduced by using 
condoms?a,b
Yes
2010: Can a person reduce the risk of getting HIV by using a condom 
every time they have sex?
UNGASS3 Can a healthy-looking person have HIV?a,b Yes
UNGASS4 Can a person get HIV from mosquito bites?a,b No
UNGASS5 Can a person get HIV by sharing food with someone who is 
infected?a,b
No
aUsed in TIE survey; bUsed in WAD 2014 survey.
 
WAD 2014 was a cross-sectional observational population-based online 
health survey on HIV-related KAP among the general young adult population 
in Finland. A commercial market research centre (Taloustutkimus Ltd.) 
performed the e-survey in 2014. The company adheres to the standards of 
International Chamber of Commerce and European Society for Opinion and 
Marketing Research aiming to improve the quality and reliability of online 
surveys. Taloustutkimus Ltd.’s online roster was established in 1997. 
Members of the roster have been recruited from previous studies that have 
sampled individuals from the PIS and the roster is constantly updated.  
A simple random sample of 5,931 individuals was selected from the 
roster. An invitation letter was sent to the individuals in the sample via e-
mail to participate in the survey. The e-mail contained a personal password 
to a Computer Aided Web Interview portal. Participation in the survey was 
voluntary. Logging into the portal and participating in the survey was taken 
as consent to participate. Answering all questions was obligatory in order to 
complete the survey. Participants did not receive any remuneration for their 
participation. The 17-item survey on HIV-related KAP included UNGASS 
indicator questions 2 to 5 and was only available in Finnish (Table 8). The 
survey was accessible from October 20–30, 2014, and was closed after the 
target number of 1,000 participants had registered. 
 HIV-related KAP of the general population in the WAD 2014 survey was 
compared to that of the young asylum seekers in the TIE survey and risk 
factors for exposure to previous HIV test were assessed (IV). 
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4.4 REGISTERS 
4.4.1 NATIONAL INFECTIOUS DISEASE REGISTER 
The National Institute for Health and Welfare in Finland governs several 
national health and social sector registers, such as the NIDR 391. The previous 
infectious disease notification system was reformed following updates in the 
Communicable Diseases Act (586/1986) in 1992 392, 393. NIDR was 
established in 1994 and was fully functional by the beginning of 1995 391, 394. 
NIDR is linked to the PIS for updates in country of birth, municipality of 
domicile and residency, nationality and death. 
Laboratories and physicians are obliged by the Communicable Disease 
Act (1227/2016) to notify specific infectious disease findings and diagnoses 
to the register 198. Accredited clinical laboratories report findings of 
approximately 70 different microbes and all findings from blood and 
cerebrospinal fluid 287. Physicians’ notifications contain additional, infection-
specific clinical and socio-demographic information relevant for 
epidemiological surveillance 124. Migration-specific parameters in the NIDR 
are infection-specific and have evolved with time, and currently include 
country of birth, nationality, year of immigration and probable country of 
infection. 
A case in NIDR is created by either laboratory’s or physician’s 
notification, or both. Finnish Personal Identification Code (PIC) and name 
are used to identify notifications belonging for the same case and the same 
person. Notification for temporary residents, such as asylum seekers and 
tourists, are registered with a temporary PIC which can be later merged with 
an official PIC automatically or manually. For hepatitis B and C, HIV and 
syphilis, notifications within 50 years are considered as a single case. 
Since 1995, there have been minor changes in the case criteria for 
hepatitis B and C, HIV and syphilis in the NIDR. Cases of CHB have been 
registered since 1994 based on laboratories’ notifications of antigen or 
antibody positivity, or physicians’ notifications of microbiologically 
confirmed cases. After 2017, CHB cases are based solely of laboratory’s 
notification.  
Cases of hepatitis C have been registered in the NIDR since 1994 based on 
laboratories’ notifications of HCV-RNA or HCVAb positivity. Since 1998 
hepatitis C cases have been formed of either laboratories’ notifications or of 
physicians’ notifications of microbiologically confirmed cases. 
Cases of HIV have been registered in the NIDR since 1983 based on either 
laboratories’ notifications of HIV-RNA, antigen or, in case of individuals over 
18 months of age, antibody positivity, or on physicians’ notifications of 
microbiologically confirmed cases. During 1983–2007, notifications of HIV 
were recorded in a separate HIV register and imported to NIDR in 2007.  
  
Syphilis cases in the NIDR have since 1994 been based on laboratories’ 
notifications of antigen or antibody positivity, or on physicians’ notifications 
of microbiologically or clinically confirmed cases. Since 2017 laboratories 
have also been able to notify NAAT-positive syphilis cases. 
The NIDR case criteria of CHB, CHC, HIV and latent syphilis have minor 
differences in comparison to the case criteria adopted by the ECDC and 
Centers for Disease Control and Prevention (CDC) 395, 396. Since 2012, ECDC 
and CDC both define CHB by HBsAg, HBeAg or HBV-DNA positivity with 
simultaneous anti-HBcAb IgM negativity, or a HBsAg, HBeAg or HBV-DNA 
positivity on two occasions at least six months apart 111, 395, 396. For CHC cases, 
ECDC requires HCV-RNA or HCV-core-Ag positivity or HCVAb positivity in 
two samples in a person older than 18 months without evidence of resolved 
infection 123, 395. CDC defines CHC according to HCV-RNA or HCV-core-Ag 
positivity with HCVAb positivity 396. Both ECDC and CDC define HIV cases 
among individuals over 18 months of age based on HIV-NAAT, antigen or 
antibody positivity and require information on confirmation of the diagnosis. 
Separate case criteria are provided for individuals less than 18 months of age. 
395, 396 CDC also considers HIV cases with only clinical diagnosis 396. For a 
latent syphilis case, both ECDC and CDC require treponemal and non-
treponemal test positivity with CDC further defining requirements for non-
treponemal test increase 395, 396. 
Publication I considered notifications of acute or chronic hepatitis B, 
hepatitis C, HIV and syphilis in NIDR between January 1, 1995 and 31st 
December 31, 2009 for persons in the Maamu survey sample who had 
immigrated after January 1, 1995. Information was retrieved based in PICs. 
Notification prevalence between the participants and non-participants was 
compared to assess the representativeness of the participants and the 
external validity of the seroprevalence estimates. A seropositive case in 
Maamu survey without a previous notification in NIDR between January 
1995 and December 2009 was considered as a missed diagnosis. 
4.4.2 HEALTHCARE PROCUREMENT REPORTING 
Since 2012, Finnish Immigration Service has procured health services 
including infectious disease screening from two national private healthcare 
service providers 397. The service providers report regularly to Finnish 
Immigration Service on the number and kind of services procured per age 
group. Monthly reporting is due by 15th of the following month resulting in a 
two to six-week delay from screening event to reporting. Finnish 
Immigration Service maintains statistics on asylum applications 31. 
Publication III used healthcare procurement register data on 
procurements of HBsAg, HIVAgAb and TrpaAb among asylum seekers in 
Finland during 2015–2016. The number and timing of screening tests 
performed among children and adult asylum seekers (numerator) was 
evaluated against the number of asylum seekers eligible for screening 
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(denominator). TrpaAb screening was used as an indicator of any blood 
screening since TrpaAb screening is recommended for all whom are screened 
for either HBsAg or HIVAgAb, or both. A target time frame for screening was 
set at of three months from arrival was adopted. 272 
4.5 STATISTICAL ANALYSES 
Statistical analyses were performed using IBM SPSS Statistics versions 22 
(II), 23 (IV) and 24 (I) and Microsoft Excel 2010 (III). Likert scales were 
recoded into bi- or trinomial variables when necessary. The null hypotheses 
were tested using Pearson’s Chi-squared (II-IV) or SPSS Complex Samples 
logistic regression (I and IV). P-values were two-tailed and considered 
significant if <0.05. Confidence intervals were calculated according to Wald 
(III) or by bootstrapping (IV). Average delay to screening was considered 
as the difference in means of arrival and screening (III). 
Multivariable logistic regression analysis was used to assess associations 
between the outcome variable and the independent variables. Missed 
diagnosis (I), refusal to test (II) and previous HIV test (IV) were used as 
dependent variables. Interactions between independent variables were tested 
for publication I. Selection of independent variables for the final regression 
models was performed with p<0.2 in the univariate comparison (I, IV) or 
using Akaike Information Criteria (II). Continuous variables were used as 
covariates and odds ratios (ORs) calculated for annual increase (I). 
Population weights were developed for population-based samples to 
balance for non-participation (I, IV). For Maamu survey, inverse population 
weights were calculated based on Bayesian Information Criterion, using age 
group, sex, origin, city of residency and marital status as auxiliary variables 
(I) 376, 398. Separate weights were developed for participants in the health 
interview with standard and short protocols, and for the health examination. 
Population weights were also developed for participants in the WAD 2014 
survey, using age group, sex and region of origin as auxiliary variables (IV). 
No population weights were developed for the Maamu pilot survey and hence 
analyses for publication II were performed without weights. 
4.6 ETHICAL REVIEW 
The study was performed according to research ethical principles outlined in 
the Declaration of Helsinki 399. Study protocols for publications I, III 
(325/13/03/2009 §146) and IV (289/13/03/00/2013 §198) were approved 
by the Coordinating Ethics Committee of the Helsinki and Uusimaa Hospital 
District. Study design of publication II received ethical approval from the 
Research Ethical Committee of the National Institute for Health and Welfare 
(§758, March 16, 2017). 
  
5 RESULTS 
5.1 BASIC CHARACTERISTICS 
Migrants with long-term residency (publications I and II) and asylum 
seekers (publications III and IV) were included in the analyses. Numbers of 
participants included in each publication are presented in Table 9. 
Table 9. Summary of the included participants. 
Publication Description of included participants Sample size Proportion of 
women; %(nb)
I Kurdish, Russian and Somali-origin adult 
migrants who immigrated after January 
1995 belonging to the Maamu sample
2,173 53.7 (1,140)a
I Kurdish, Russian and Somali-origin adult 
migrants who immigrated after January 
1995 and who participated in Maamu survey 
health examination
1,071 53.9 (583)a
I Kurdish, Russian and Somali-origin adult 
migrants who immigrated after January 
1995 and who were screened for HBsAg, 
HCVAb, HIVAgAb or TrpaAb in Maamu 
survey
1,000 54.6 (553)a
II Kurdish, Russian and Somali-origin adults 
migrants resident in Helsinki who 
participated in Maamu survey or Maamu 
survey pilot
386 57.6 (220)
III Asylum seekers in Finland during 2015–
2016
37,614 20.8 (7,946)
III Asylum seekers in Finland during 2015–
2016 screened for HBsAg
22,144 NA
III Asylum seekers in Finland during 2015–
2016 screened for HIVAgAb
13,768 NA
III Asylum seekers in Finland during 2015–
2016 screened for TrpaAb
22,016 NA
IV Asylum seekers aged 20 to 25 years who 
participated in TIE survey
47 21.7 (10)
IV General population aged 20 to 25 years who 
participated in the WAD 2014 survey
485 49.2 (301)a
aWeighted proportion; bCrude n; NA = Not available
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Data on migrant specific vulnerabilities was available for Kurdish, Russian 
and Somali-origin migrants in the Maamu survey and to a limited extent for 
young adult asylum seekers in the TIE survey (I, IV). 
At the time of the Maamu survey, Russian-origin migrants were older 
(average 38.6 years) than migrants of Kurdish (34.9 years) or Somali (mean 
32.4 years) origin (p<0.01) (I). Migrants of Russian origin were also older at 
the time of immigration (average 29.6 years) as compared to Kurdish 
(25.5 years) or Somali origin (23.6 years) migrants (p<0.01). 
Reasons for immigration differed significantly between the migrant 
populations with long-term residency. Only a percentile of Russian-origin 
migrants had received residency permit based on a refugee status compared 
to Kurdish or Somali-origin migrants of whom three fourths had immigrated 
as refugees or asylum seekers (p<0.01). A lower proportion of Somali-origin 
migrants were employed at the time of the survey (16.1%) compared to 
Kurdish or Russian-origin migrants (37.7% and 47.8% respectively, p<0.01). 
Level of education differed significantly between migrant populations in 
the Maamu survey. Secondary education or more was reported by 78.5% of 
the Russian, 41.7% of Kurdish and 18.8% of Somali-origin migrants (p<0.01). 
Good ability to read in Finnish or Swedish was reported by 83.9% of all 
participants to the Maamu survey without differences according to origin 
(p=0.89). (I) The proportion of individuals with only primary education was 
higher among young asylum seekers in the TIE survey in comparison to 
young adult general population in the WAD 2014 survey (62.2 vs. 13.4% 
respectively, p<0.05). One-sixth (17.0%) of young adult asylum seekers could 
read poorly or not at all in their mother tongue and one-fourth (23.4%) had 
poor writing skills. (IV)  
Migrant women of Kurdish, Russian or Somali origin were older (average 
36.4 vs. 34.5 years, p=0.03) and had resided in Finland for a longer period 
(average 9.4 vs. 8.7 years, p<0.01) than men. Somali-origin women were less 
educated than men (11.3 vs. 30.7% with tertiary education respectively 
p<0.01) and had poorer literacy (77.9 vs. 93.4% literate in Finnish or 
Swedish respectively, p<0.01). A significantly larger proportion of Russian 
origin women reported previous abortions (55.8%) compared to Kurdish 
(22.4%) or Somali (1.3%) origin women (p<0.01). Proportion of women with 
at least one previous delivery did not differ between migrant populations. (I) 
The proportion of women in the TIE survey was smaller than the weighted 
proportion of women in the WAD 2014 survey (Table 9) (IV).  
History of previous IDU was rare with only two persons reporting lifetime 
injections. Nearly all (97.5%) Russian-origin migrants, 59.6% of Kurdish 
migrants and 15.7% of Somali-origin migrants reported VFR return travelling 
to previous country of origin. 
  
5.2 PARTICIPATION AND ACCEPTABILITY OF 
SCREENING 
5.2.1 PARTICIPATION (I) 
Maamu health interview and examination survey invited 3,000 Kurdish, 
Russian and Somali-origin adult migrants randomly selected from the PIS. 
Of them, 827 (27.6%) had immigrated before January 1, 1995, and were 
excluded from the analyses (Figure 3). Participation in the survey was 
highest among Russian-origin migrants in comparison to Kurdish and 
Somali-origin migrants (p<0.01). Of the survey participants, 1,071 took part 
in the health examination and were offered screening for hepatitis B and C, 
HIV and syphilis.  
 
 
Figure 3 Flow chart on participation in hepatitis B and C, HIV and syphilis screening, and 
register linkage in the Maamu survey.  PIS=Population Information System. 
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Notification prevalence of acute or chronic hepatitis B, HCV or syphilis did 
not differ among the 1,000 participants and 1,173 non-participants in the 
Maamu survey blood screening (p = 0.39, 0.99 and 0.59 respectively). No 
notifications of HIV were observed among the Maamu survey sample.  
Health examination participation rate was lower among residents of 
Helsinki (36%, n=334) and in the pilot survey (35%, n=52) than among all 
participants in Maamu survey (49%, n=1,071, Figures 3 and 4). 
 
 
Figure 4 Flow chart on participation in HIV screening during Maamu survey and pilot survey 
in Helsinki. PIS=Population Information System. 
5.2.2 ACCEPTABILITY OF SCREENING (I, II) 
Of all the Maamu survey participants who had immigrated after January 
1995, 1,071 (58.1%) took part in the health examination and were offered 
screening for hepatitis B and C, HIV and syphilis (Figure 3). At least one 
screening test was accepted by 1,000 participants (93.4%) (Table 10). 
Acceptability of any test or specific tests was not associated with origin or 
age. Acceptability of any test was significantly higher among women (94.9%) 
in comparison to men (91.6%, p=0.03). (I) 
Acceptability of HIV testing increased from 76.9% in the pilot survey to 
94.6% in the Maamu survey in Helsinki after introduction of enhanced pre-
test counselling (Figure 4). Improvement was mostly due to increase in 
acceptability among the Russian-origin migrants. (II) 
Predictors for the acceptability of HIV screening were evaluated among 
both the participants in Maamu survey health examination in Helsinki and 
pilot survey. In multivariate logistic regression model, lower risk of refusal of 
HIV screening was associated with unemployment (adjusted OR 0.35, 95% 
  
CI 0.15–0.82), poor ability to understand spoken Finnish or Swedish (0.09, 
0.01–0.82) and enhanced pre-test counselling (0.11, 0.04–0.27). A 
borderline significant association was observed with living alone (0.21, 0.04–
1.0). (II) 
Table 10. Acceptability of screening for hepatitis B/C, HIV and syphilis among the 
participants in the Maamu health examination; % (n). 
HBsAg/ HCVAb HIVAgAb TrpaAb Any test
Kurdish 93.2 (413) 91.9 (409) 92.6 (412) 93.3 (415)
Russian 93.1 (323) 92.8 (322) 92.5 (321) 93.4 (324)
Somali 93.2 (260) 90.0 (251) 91.4 (255) 93.5 (261)
Total 93.2 (996) 91.7 (982) 92.3 (988) 93.4 (1,000)
5.3 BURDEN OF HEPATITIS B AND C, HIV AND 
SYPHILIS 
5.3.1 SEROPREVALENCE (I, III) 
Seroprevalence of HBsAg, HIV and TrpaAb was assessed among participants 
in the Maamu survey (I) and among asylum seekers to Finland in 2015–2016 
(III). HCVAb seroprevalence was assessed only in the Maamu survey (I). 
Among Kurdish, Russian and Somali migrants who had immigrated after 
1995, the overall weighted seroprevalence of HBsAg was 2.3% [95% CI 1.5–
3.5%], HCVAb 1.7% [1.0–2.9%], and TrpaAb 1.3% [0.7–2.3%]. No HIV cases 
were identified among the participants in the Maamu survey. (I) 
Significant differences in seroprevalence of HBsAg, HCVAb and TrpaAb 
between Kurdish, Russian and Somali migrant populations were observed 
(Table 11). In general, Kurdish-origin migrants had low levels of infection 
and none of the Kurdish women tested positive for HBsAg, HCVAb, HIV or 
TrpaAb. As compared to the Kurdish migrant population, Somali-origin 
migrants had significantly higher HBsAg prevalence and Russian-origin 
migrants significantly higher TrpaAb seroprevalence. Russian women had 
significantly higher TrpaAb seroprevalence than men (4.5 vs. 0.6% 
respectively, p=0.04). (I) 
Seroprevalence of HBsAg and TrpaAb were similar among all participants 
in the Maamu survey and all asylum seekers in Finland during 2015–2016. 
However, HBsAg seroprevalence among Somali-origin migrants in Maamu 
survey was significantly higher than observed among all asylum seekers 
(Table 11). (I, III) 
Trends in seroprevalence varied with age for different infections and 
migrant populations despite of the sparsity of the data (Table 12). The overall 
weighted seroprevalence of HBsAg was not associated with age among all 
participants in the Maamu survey. HBsAg seroprevalence among the 
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youngest age cohort of 18–29 years was 1.8% [95% CI 0.8–4.0%], among the 
30–44 year-olds 2.1% [1.0–4.3%], and among the 45–64 year-olds 3.4% 
[1.7–6.5%] (p=0.11 using age as a covariate). For Somali-origin migrants 
however, a statistically significant increase in HBsAg seroprevalence with age 
was observed (OR 1.05 by year, 95% CI 1.01–1.09). (I) 
Table 11. Seroprevalence of HBsAg, HCVAb, HIVAgAb and TrpaAb among adult Kurdish, 
Russian and Somali migrants who immigrated after 1995 and among all asylum 
seekers in Finland during 2015-2016; % [95% confidence interval] (crude n). 
 Maamu survey; %a [95% CI] (nb) Asylum seekers; 
% [95% CI] (n)  
ntot=38 134 
 Kurdish; n=415 Russian; n=324 Somali; n=261 
HBsAgc 0.4 [0.1–1.5] (2) 1.7 [0.7–4.3] (5) 6.0 [3.6–9.9] (16) 1.4 [1.3–1.6] (318) 
HCVAbc 0.1 [0.0–0.5] (1) 4.1 [2.2–7.3] (12) 1.3 [0.4–4.1] (3) NA 
HIV-AgAbd 0 0 0 0.3 [0.1–0.4] (45) 
TrpaAbe 0.3 [0.1–1.9] (1) 2.9 [1.5–5.6] (9) 1.0 [0.2–3.8] (2) 1.0 [0.8–1.1] (211) 
ᵃPopulation weighted seroprevalence; bCrude n; cp<0.01 between Maamu migrant groups; 
dp<0.05 between overall seroprevalence in Maamu survey and among asylum seekers; 
ep<0.05 between Maamu migrant groups; NA = Not available. Categories of hepatitis B 
endemicity: green=very low (<0.5%), yellow=low (<2%), orange=low-intermediate (2–4.99%), 
red=high-intermediate (5–7.99%) 55, 92. Categories of hepatitis C endemicity: green=very low 
(<1%), yellow=low (1–2%), orange=intermediate (2–3%), red=high (3–5%) 120. 
 
Conversely, the overall weighted seroprevalence of HCVAb and TrpaAb 
increased with age among all participants in the Maamu survey. HCVAb 
seroprevalence increased from 0.7% [95% CI 0.2–3.0%] among the youngest, 
to 1.5% [0.6–3.8%] among the middle, and finally to 3.5% [1.8–6.8%] among 
the oldest age group (p=0.01). After stratification with origin, increasing 
trend in HCVAb seroprevalence with age persisted among Kurdish (OR 1.07 
by year, 95% CI 1.06–1.09) and Somali-origin migrants (1.16, 1.09–1.23) 
(Table 12). (I) 
TrpaAb seroprevalence was 0.4% [0.1–2.1%] among the youngest, 1.2% 
[0.4–3.2%] among the middle, and 3.1% [1.5–6.4%] among the oldest age 
group (p<0.01). TrpaAb seroprevalence increased significantly with age 
among migrants of Russian (OR 1.04 by year, 95% CI 1.01–1.08) and Somali 
(1.27, 1.03–1.57) origin. In contrast, a decreasing trend with age in TrpaAb 
seroprevalence was observed among Kurdish migrants (0.84, 0.82–0.86). 
(Table 12) (I) 
For asylum seekers, HBsAg seroprevalence was significantly higher 
among adolescents aged 16 to 17 years and adults in comparison to children 
under 16 years of age (Table 13). Adults had also higher HIV and TrpaAb 
seroprevalence rates in comparison to children. No cases of HIV were 
identified among asylum-seeking children less than 18 years of age. (III) 
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5.3.2 BURDEN OF DISEASE (I) 
Burden of hepatitis B and C, HIV and syphilis was estimated by extrapolating 
from the observed weighted seroprevalences in Maamu survey to the total 
adult Kurdish, Russian and Somali-origin first-generation migrant 
populations in Finland in the end of 2017 30 (I). Russian migrants 
represented the largest migrant population followed by Kurdish and Somali-
origin migrants (Table 14). Highest number of HBsAg, HCVAb and TrpaAb 
positive cases was estimated to occur among Russian-origin migrants. 
Burden of HIV could not be estimated as no cases of HIV were identified 
among participants in the Maamu survey. 
Table 14. Estimated burden of HBsAg, HCVAb and TrpaAb seroprevalence and missed 
diagnoses among 18 to 64-year-old Kurdish, Russian and Somali-origin migrant 
populations living in Finland on Dec 31, 2017 30; n [95% confidence interval].
Kurdisha Russianb Somalic
Total migrant population in Finland; 
aged 18 to 64 years
19,041 57,600 9,611
HBsAg Total HBsAg-positive 76 [19–286] 979 [403–2,477] 577 [346–951]
Missed HBsAg diagnoses 76 [19–286] 403 [115–1,267] 288 [135–586]
HCVAb Total HCVAb-positive 19 [0–95] 2,362 [1,267–4,205] 125 [38–394]
Missed HCVAb diagnoses 19 [0–95] 1,728 [864–3,398] 29 [0–183]
TrpaAb Total TrpaAb-positive 57 [19–362] 1,670 [850–3,226] 96 [19–365]
Missed TrpaAb diagnoses 57 [19–362] 1,382 [691–2,822] 96 [19–365]
aFirst-generation 18 to 64 year old migrants with a country of birth Iraq or Iran 30; bFirst-
generation 18 to 64 year old migrants with a country of birth Russia or Former Soviet Union 30;
cFirst-generation 18 to 64 year old migrants with a country of birth Somalia 30.
5.4 IMPLEMENTATION OF SCREENING 
5.4.1 SCREENING COVERAGE (I, III, IV) 
Coverage of infectious disease screening was assessed in publications I and 
III, and participation in previous HIV testing in publications I and IV. 
Self-reported participation in infectious disease screening after arrival 
was assessed during Maamu survey health interview. Weighted coverage of 
infectious disease screening was 91.9% [95% CI 87.3–93.8%] among 
Kurdish, 49.2% [6.3–93.3%] among Russian and 81.4% [73.8–87.1%] among 
Somali-origin migrants who had immigrated as asylum seekers or refugees 
after 1995 (p=0.01 between groups), and the overall weighted coverage was 
87.5% [83.9–90.3%]. No differences in self-reported weighted screening 
  
coverage was observed between men and women (p=0.97) nor according to 
age (p=0.86). (I) 
Coverage of infectious disease screening was assessed also among asylum 
seekers in Finland during 2015–2016 using syphilis screening as a proxy for 
any performed screening of any blood-borne and sexually transmitted 
infection (III). Of the 37,614 asylum seekers included in the study, 95.2% 
were eligible for the screening of CHB, HIV or syphilis based on country of 
origin. No difference in the eligibility for screening between children and 
adults was observed. The overall coverage of screening was 60.6% with 
22,016 TrpaAb tests performed during 2015–2016. The screening coverage 
was 60.4% among eligible adults and 61.4% among eligible children (p=0.26 
between age groups). (III) 
One-third (31.4%) of participants in the Maamu survey reported previous 
HIV testing with significant differences between migrant populations of 
different origin (p<0.01) (Table 15) (I).  
Table 15. Proportion reporting previous HIV testing; % [95% confidence interval].
Study population Total Women Men pa
M
aa
m
u Kurdish migrantsb 12.2 [9.5–15.5] 7.1 [4.4–11.4] 16.1 [12.0–21.3] <0.01
Russian migrantsb 53.4 [47.4–59.3] 64.5 [57.1–71.3] 37.3 [28.3–47.3] <0.01
Somali migrantsb 34.5 [28.5–41.1] 31.0 [23.8–39.1] 39.9 [29.5-51.2] 0.19
Asylum seekers in TIE 
survey
23.4 30.0 22.2 0.61
General population in 
WAD 2014 surveyb,c
18.0 [14.9–21.7] 27.9 [22.9–33.4] 8.5 [5.3–13.4] <0.01
ap between sexes; bWeighted prevalence; cSelf-initiated HIV testing.
 
Women reported previous HIV testing more often than men both in Maamu 
survey and among the young adult general population in the WAD 2014 
survey (Table 15). Overall weighted prevalence of previous HIV testing was 
35.1% [95% CI 31.2–39.1%] among migrant women and 27.3% [23.2–31.9%] 
among migrant men in Maamu survey (p=0.01). In contrast, Kurdish men 
reported significantly higher rate of previous HIV testing in comparison to 
women. Age was not associated with previous HIV testing among 
participants in the Maamu survey (p=0.75). (I) 
Among young adult asylum seekers in the TIE survey, no differences in 
previous HIV testing were observed according to gender or country of origin. 
Answering correct to all UNGASS indicator questions on HIV knowledge was 
borderline associated with previous HIV testing among participants to the 
TIE survey (p=0.09). (IV) 
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5.4.2 DELAY TO TEST AND MISSED DIAGNOSIS (I, III)
Delay to diagnosis or test and the number of missed diagnoses were 
evaluated in Maamu survey (I) and among all asylum seekers during 2015–
2016 (III). Predictors of missed hepatitis B or C, or syphilis diagnosis were 
assessed in Maamu survey (I).  
Of all seropositive findings in Maamu survey, one fifth (19.6%, n=11) had 
been notified to the NIDR within one year of immigration, two-fifths (39.3%, 
n=22) before the Maamu survey and 60.7% (n=34) did not have a prior 
notification in the NIDR and where thus considered missed diagnoses 
(Figure 5). The majority of hepatitis C and syphilis dignoses were notified 
over a year after immigration or diagnosed in the Maamu survey.  Seven 
persons with TrpaAb-positive finding in Maamu survey had immigrated 
before 2005, when the reverse algorithm of syphilis testing and diagnosis 
with TrpaAb was widely implemented in Finland. (I) 
 
 
Figure 5 Timing of the diagnosis in relation to arrival; %. Numbers inside columns represent 
number of cases. 
Missed diagnoses were identified among 33 individuals (3.3%) tested in the 
Maamu survey. Weighted prevalence of any missed diagnosis was 0.8% [95% 
CI 0.3–2.1%] among the Kurdish, 5.8% [3.6–9.2%] among the Russian and 
4.2% [2.3–7.7%] among the Somali-origin migrants. Weighted prevalence of 
missed hepatitis B diagnosis was 3.0% [1.4–6.1%] among Somali-origin 
migrants. All diagnoses among Kurdish migrants had been missed. 
Extrapolating the prevalence of missed diagnosis to the total migrant 
populations in Finland, in total more than 4,000 diagnoses of CHB, HCVAb 
  
or TrpaAb have been missed, the majority of these among Russian migrants 
(Table 14). (I) 
In complex samples multivariate logistic regression, the risk for missed 
diagnosis was associated with Russian-origin (adjusted OR 7.74, 95% CI 
1.55–38.75), marital status among the Somali-origin migrants (0.05, 0.01–
0.36), daily smoking (3.71, 1.59–8.68) and self-reported previous blood-
borne infectious disease diagnosis (9.00, 2.05–39.44) (I). 
During 2015–2016, adult asylum seekers arrived in Finland earlier than 
children: the median date of asylum appeal was September 2015 for adults 
and October 2015 for children (Figure 6). Among screened adults, the 
estimated average delay from arrival to TrpaAb screening was 91 days, and 
47 days for children. For adults, the blood screenings were delayed from the 
target time-frame from November 2015 until July 2016. For children, the 
blood screenings remained within the three-month target time frame 
throughout the follow-up period 2015–2016. (III) 
 
 
Figure 6 Numbers of arrived of asylum-seeking adults and children from blood-screening 
eligible countries, and number of TrpaAb screenings performed for adults and 
children by month in 2015–2016.
Based on the screening coverage and the observed seroprevalence rates, 
approximately 194 [95% CI 180–222] hepatitis B diagnoses, 42 [10–55] HIV 
Results 
76 
diagnoses and 139 [111–152] TrpaAb-positive cases were missed among the 
asylum seekers to Finland in 2015–2016. (III) 
5.5 HIV RELATED KNOWLEDGE, ATTITUDES AND 
PRACTICES (IV) 
TIE survey involved 68 participants, of whom all 47 individuals between 20 
to 25 years of age were included in the analyses. Similarly, of the 1,011 
participants in the WAD 2014 survey, all 485 aged between 20 to 25 years 
were included in the study.  
Among asylum seekers, SSA origin, female gender and higher education 
were associated with better knowledge. Asylum seekers of SSA origin had 
higher UNGASS composite score in comparison to other regions of origin 
(p<0.01). Female asylum seekers had a borderline higher UNGASS 
composite score (p=0.05) and a higher proportion knew that HIV cannot be 
transmitted by sharing a meal (UNGASS 5) as compared to men (p<0.05). 
Asylum seekers with secondary education were more knowledgeable 
regarding benefits of condom use (UNGASS 2) in comparison to persons with 
lower education (p<0.01). 
HIV-related KAP was compared between young asylum seekers in the TIE 
survey and young adult general population in the WAD 2014 survey. The 
UNGASS composite score representing a measure of comprehensive HIV 
KAP, was significantly lower among the young asylum seekers in comparison 
to young adult general population (6.4 vs. 50.3% respectively, p<0.05) (Table 
16). 
In general, young adult asylum seekers had more gaps in specific 
questions related to HIV knowledge as compared to general population 
young adults. The differences between populations predominantly persisted 
after stratification by gender and level of education. However, among highly 
educated men, the gaps disappeared with respect to knowledge that risk of 
HIV transmission can be reduced by using a condom (UNGASS 2) and that 
HIV cannot transmit through kissing.  
Attitudes to HIV were equally supportive among young asylum seekers 
and young adult general population. Of the young asylum seekers, 45.7% 
[95% CI 28.9–62.1%] would support a friend living with HIV and 58.8% 
[54.0–63.4%] of the general population young adults would do as well. No 
differences in attitudes related to HIV were observed between sexes or levels 
of education. 
Young adults were asked about their preferred sources of HIV-related 
information. Young adult asylum seekers named television (59.6%, 95% CI 
46.2–74.5%), the internet (53.2%, 38.8–67.4%) and health workers (46.8%, 
33.3–60.9%) as the three most popular sources of information, with no 
significant gender differences. Among the general population, the most 
popular sources of information were school nurse (75.4%, 71.0–79.3%), 
  
parents (51.6%, 46.8–56.3%) and events organized at schools (47.5%, 42.7–
52.2%). General population women preferred health education by parents 
and through school events as compared to men (p<0.05 and <0.01 
respectively). For general young adult population men, teachers were the 
third most popular source of information on sexual health and HIV (48.1%, 
40.6–55.6%). 
Table 16. HIV knowledge, attitudes and practices among young asylum seekers (TIE 
survey) and young adult general population (WAD 2014 survey). Mean %; 95% 
confidence interval, p between groups.
TIE survey
WAD 2014
survey p
KNOWLEDGE
UNGASS composite score (indicators 2-5) 6.4 [0–14.0] 50.3 [45.5–55.1] <0.05
Risk of HIV transmission can be reduced by 
using a condom (UNGASS 2) 59.0 [43.9–74.4] 87.5 [85.2–89.5] <0.05
A healthy looking person can have HIV 
(UNGASS 3) 31.0 [17.8–45.2] 99.1 [97.9–99.6] <0.05
A person cannot get HIV from mosquito 
bites (UNGASS 4) 26.8 [13.5–42.5] 56.3 [53.0–59.7] <0.05
A person cannot get HIV by sharing a meal 
with someone who is infected (UNGASS 5) 38.1 [23.4–55.3] 88 [85.6–90.0] <0.05
HIV can be treated 26.8 [13.6–42.1] 83 [77.0–87.7] <0.05
A person cannot get HIV through kissing 42.9 [28.2–57.8] 83.4 [77.4–88.2] <0.05
ATTITUDES
Supportive reaction to HIV positivity 45.7 [28.9–62.1] 58.8 [54–63.4] >0.05
 
HIV related practices were assessed by assessing participation in previous 
HIV testing. The results are presented in chapter 5.4.1 “Screening coverage”. 
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6 DISCUSSION 
This study showed that migrant populations in Finland are heterogeneous 
with respect to seroprevalence of hepatitis B and C, HIV and syphilis. Some 
migrants are especially vulnerable to blood-borne and sexually transmitted 
infectious: they have higher seroprevalence rates in comparison to the 
general population and a substantial proportion of the infections are 
undiagnosed. This study identified barriers and opportunities for prevention 
and early diagnosis of blood-borne and sexually transmitted infections 
among migrants. Poor knowledge about transmission, prevention and 
treatment of infections might encourage risk behaviours and delay testing. 
Current screening guidelines do not target all migrants at increased risk. 
Furthermore, they are not implemented efficiently and coverage of screening 
among migrants is suboptimal. As provider-initiated testing is well-accepted 
among migrants, healthcare providers should not miss opportunities to offer 
testing. 
6.1 FEASIBILITY OF TESTING IN POPULATION HEALTH 
SURVEYS 
Maamu survey was the first population-based health survey in Finland to 
include infectious disease screening and, to the best of our knowledge, the 
first survey globally to assess non-participation based on history of infectious 
diseases. The non-participation analysis demonstrated that the participants 
and non-participants in the Maamu survey did not differ from each other as 
evaluated by previous notification prevalence of hepatitis B or C, HIV or 
syphilis. The finding implies that with respect to prevalence of infectious 
diseases, results from the Maamu survey are externally valid and 
generalizable to the total migrant population in Finland. (I) 
Incidence of chronic and often asymptomatic infectious diseases such as 
CHB, CHC, HIV and syphilis reflects testing patterns more than it does 
actual incidence of infections 95. Hence, reports of screening yields are 
valuable in establishing prevalence of infections in asymptomatic 
populations.  
Migrant population-based surveys assessing infectious disease prevalence 
in general migrant population are sparse 140, 329. Whole population analyses 
of infectious disease prevalence are available among selected groups of 
migrants such as asylum seekers and refugees but tend to over- or 
underestimate the prevalence in general populations through selection bias 
94, 160. 
Population-based health surveys provide an invaluable asset in estimating 
the disease burden among general populations. Prevalence of infections 
  
among at-risk populations such as PWID, prisoners, MSM, paid blood 
donors, health service users or refugees might overestimate the prevalence as 
compared to the general populations, and hence prevalence studies among 
these populations are often excluded from reviews and meta-analyses 96, 103, 
118, 119, 147. Voluntary blood donors have usually lower burden of infections 
than the general population due to pre-selection 41. ANS yields describe the 
prevalence of infections among fertile women, but represent often the best 
guess of seroprevalence among the general population 147.  
Acceptability of the provider-initiated opt-in multiphasic hepatitis B and 
C, HIV and syphilis screening was high among all migrant populations in the 
Maamu survey and similar or higher than in most other surveys among 
migrant populations 142, 208, 256, 264, 303, 304, 324 . In Maamu survey, screening for 
was accepted better by women in comparison to men. (I, II) Previous studies 
have found migrant women to have higher acceptance rates as compared to 
men partially owing to increased exposure to testing in universal opt-out 
ANS settings 142, 207, 288. However, in a British cross-sectional study among 
clients of a sexual health clinic, migrant and ethnic minority men had higher 
acceptability of HIV testing in comparison to women, which led the authors 
to speculate that women’s increased exposure to testing in ANS and other 
settings might actually increase the refusal rate 400. 
Association of acceptability of testing with determinants of migrants’ 
lower socio-economic status such as unemployment and poor language skills 
might reflect migrants self-perceived infectious disease risks, patterns of 
trust towards health providers or unmet demand for health services (II). An 
opposite observation was made in a UK study among clients of sexual health 
clinics where risk for refusal of HIV testing was higher for migrants living in 
deprived areas 400. Additionally, other studies have found increased 
acceptability of HIV testing among migrants to associate with MSM, 
increased risk behaviour, rapid testing, testing in primary care or in 
community settings 142, 207, 208, 400. A review among general population in the 
UK concluded that HIV testing uptake was higher among symptomatic than 
asymptomatic individuals 401. 
Acceptability of opt-in HIV testing was significantly improved by 
enhanced pre-test counselling adopted after findings from the pilot survey 
(II). Although opt-in PITC strategies have been demonstrated high 
acceptability among migrants, recently several guidelines recommend 
provider-initiated routine or opt-out strategies to further increase HIV 
testing coverage 138, 402. As acceptability of testing influences the effectiveness 
of screening interventions, health professional should be trained in 
negotiating testing especially with persons without apparent risk-factors 208. 
The moral principle of reciprocity can be used to explain acceptability of 
screening and to justify screening programmes. The expectations and 
benefits of the individual and the public meet when an individual’s losses for 
participation in infectious disease screening are compensated by benefits 
gained from access to health services, for example. 277 The reciprocity 
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principle might thus explain why, as an example, forced migrants have 
previously been reported to have higher acceptance rates of infectious 
disease screening in comparison to other migrant populations 208. 
Finally, high acceptability of testing in the Maamu survey supports 
inclusion of infectious disease screening in future population health surveys. 
6.2 SEROPREVALENCE AND BURDEN OF DISEASE 
6.2.1 HEPATITIS B 
HBsAg seroprevalence rates differed among included migrant populations in 
the Maamu survey. Very low (<0.5%) HBsAg seroprevalence was observed 
among Kurdish migrants, low (<2%) seroprevalence among Russian 
migrants and high-intermediate (5–7.99%) seroprevalence among Somali-
origin migrants (Table 11). (I) HBsAg seroprevalence rate among the total 
asylum-seeker population was low (<2%, III). As compared to the estimated 
Finnish general population HBsAg seroprevalence of <0.2%, HBsAg 
seroprevalence was higher among Russian (1.7%) and Somali (6.0%) origin 
migrants, and among asylum seekers (1.4%) (I, III). 
The observed HBsAg seroprevalence rates among Kurdish, Russian and 
Somali-origin migrants were comparable or lower than observed in previous 
research in countries of origin and among migrants in high-income countries 
40, 96, 97, 102, 107 (Tables 1 and 11) (I).  
Similarly, HBsAg seroprevalence among asylum seekers in Finland was 
comparable or lower than in previous seroprevalence studies among asylum 
seekers and refugees in Europe during the migrant crisis. These studies have 
reported HBsAg seroprevalence rates between 0.7–12.2% 150, 158, 160, 294, 324, 336, 
337, 339-343, 401, 403. The majority of HBsAg seroprevalence studies among 
asylum seekers included general populations 158, 160, 294, 336, 337, 339, 342, 343, 401; 
some were conducted in healthcare settings 324, 340, 341, 403; and few included 
only children 342, 343.  
Previous research has found HBsAg seroprevalence among asylum 
seekers to mirror that of the countries of origin: higher rates have been 
observed among SSA-origin asylum seekers and lower rates among persons 
originating from the Middle East and North Africa 158, 294, 324, 336, 339-341, 403. 
Almost 90% of the asylum seekers to Finland during 2015–2016 originated 
from Middle East and North Africa including Afghanistan, which is likely to 
explain the relatively low HBsAg prevalence observed as compared to reports 
from other European countries (III). 
Selective migration of healthy individuals – the so-called healthy migrant 
phenomenon – could explain the comparable or lower HBsAg seroprevalence 
rates among migrants of Kurdish, Russian and Somali origin and among 
asylum seekers in Finland as compared to previous reports 6. Moreover, the 
  
results suggest that HBsAg seroprevalence rates reported previously among 
in-country populations and migrants can be used to estimate the HBV 
burden among migrant populations in Finland. 
HBsAg seroprevalence rates increased with age among Somali-origin 
adult migrants and among asylum seekers (Tables 12 and 13) (I, III). Of note 
is that the strength of the prediction is compromised due to sparsity of the 
data. Increasing HBsAg seroprevalence with age was observed among asylum 
seekers in Germany also 403. These observations are somewhat contradictory 
to findings from a systematic review and a meta-analysis on global age-
specific HBsAg seroprevalence. Ott et al. observed decreasing HBsAg 
seroprevalence with age in Eastern and Sub-Saharan Africa and Middle East 
and North Africa both in 1990 and in 2005. 103 Considering that universal 
HBV vaccination program in Somalia has only been available since 2013 and 
previous studies have observed low coverage of HBV vaccine among Somali-
origin migrants, the increasing HBsAg seroprevalence with age could suggest 
transmission in adulthood and possibly post-migration 294, 345. 
During 1990–2005, the global HBsAg seroprevalence rates in the young 
age groups decreased, reflecting implementation of universal HBV 
immunization programs 103. Indeed, the significantly lower HBsAg 
seroprevalence in asylum-seeking children as compared to asylum-seeking 
adults or adult Kurdish, Russian and Somali-origin migrants might reflect 
implementation of universal childhood HBV vaccination in the countries of 
origin 345. The higher HBsAg seroprevalence among 16–17 year old asylum 
seekers in comparison to younger children can partly be explained by 
misreporting of age. Approximately every sixth of unaccompanied minor 
asylum seekers in Finland during 2015–2016 has later been deemed over 18 
years of age 404. The implementation of universal HBV vaccination programs 
in migrants’ countries of origin is likely to influence the epidemiology of 
hepatitis B among migrants in Finland in the future 57, 345. 
Considering evidence from previous systematic reviews that support of 
CHB screening in populations with HBsAg prevalence as low as 0.3%, 
selective screening of CHB among Kurdish, Russian and Somali-origin 
migrants is likely to be cost-effective 41, 208, 276. Of note, however, is that cost-
effectiveness of screening depends greatly on the operational effectiveness of 
screening (Figure 2) 208. 
The burden of hepatitis B was estimated by extrapolating population 
prevalence to the size of the migrant population. As migrants born in Russia 
or the FSU represent the largest migrant population in Finland, Russian-
origin migrants had also the largest hepatitis B burden despite having low 
HBsAg seroprevalence (Table 14) (I) 30. Migrants of Somali origin also had a 
substantial number of hepatitis B infections.  
Keeping in mind that the vast majority of Russian-origin migrants in 
Finland are not refugees, they fall outside current hepatitis B screening 
recommendations for asylum seekers and refugees 272, 376. Municipalities 
offer health examinations for refugees, asylum seekers and other migrants 
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with permanent residency and in need of integration and employment 
services. 269 Labour migrants, students and family members with migrant 
origin are encountered unsystematically in occupational healthcare, student 
healthcare and in ANS.  Furthermore, Russian-origin migrants use parallel 
healthcare services in countries of origin and may thus avoid screening in 
Finland 226. Indeed, Karvonen et al. have estimated that the current hepatitis 
B screening guidelines fail to catch more than two-thirds of the migrants with 
CHB immigrating to Finland annually 57, 272. 
Finally, the observed HBsAg seroprevalence rates and burden of hepatitis 
B suggest that in the presence of targeted HBV vaccination programme in 
Finland, screening of hepatitis B is essential in identifying persons at risk 
who would benefit from vaccination. 
6.2.2 HEPATITIS C 
Seroprevalence of HCVAb was very low (<1%) among Kurdish migrants, low 
(1–2%) among Somali migrants and high (3–5%) among Russian-origin 
migrants (I). In comparison to the estimated general population HCV 
prevalence in Finland (0.3%), both Russian and Somali-origin migrants had 
higher HCVAb seroprevalence (4.1% and 1.3% respectively) 124. 
The observed HCVAb seroprevalence rates among Kurdish and Russian-
origin migrants were similar as previously reported among general 
populations in countries of origin and among migrants in high-income 
countries 39, 119 (Tables 1 and 11) (I). Mohd Hanafiah et al. estimated a 
comparable overall HCVAb seroprevalence of 2.9% in the FSU countries 118. 
WHO presented a comparable HCVAb prevalence estimate of 0.9% for Iran 
and 3.2% for Iraq in 1999 120, 363.  
Previous studies among asylum seekers and refugees in Europe during the 
migrant crisis have found HCVAb seroprevalences to range between 0–6% 
150, 160, 294, 324, 338-341, 401, 403. Most of the studies included general asylum seeker 
populations 160, 294, 338, 339, 401 and some were conducted in healthcare settings 
324, 340, 341, 403. In Italy, HCVAb seropositivity was reported especially among 
asylum seekers and refugees from Eastern Europe, India and Pakistan 340. 
An increasing trend of HCVAb seroprevalence with age was observed 
among Kurdish and Somali-origin migrants that could be explained by 
prolonged time of exposure and accumulation of risk factors for transmission 
(Table 12) (I). Among Russian-origin migrants, HCVAb seroprevalence was 
not associated with age. The estimates are, however, vulnerable to 
uncertainties due to sparse data. Previously, older age has been observed as a 
predictor of HCVAb seropositivity among migrants and refugees 120, 403. 
Systematic reviews have concluded that selective screening of hepatitis C 
among migrants from intermediate and high HCV prevalence areas (HCVAb 
prevalence >2%) is cost-effective. However, as migrant-population-specific 
assessments of HCVAb screening cost-effectiveness were sparse, HCVAb 
  
screening is likely to be cost-effective also at lower population seroprevalence 
thresholds. 41, 208, 301  
Considering the observed HCVAb seroprevalence rates, implementation 
of HCV screening among Russian-origin migrants in Finland is likely to be 
cost-efficient (I). Cost-effectiveness of HCVAb screening among Somali-
origin migrants should be evaluated. Cost-effectiveness of HCV screening 
among migrants is influenced by the operational effectiveness of the 
programme and, especially in case of HCV, drug prices (Figure 2) 208. 
As migrants born in Russia or the FSU represent the largest migrant 
population in Finland, the burden of hepatitis C was also largest among 
migrants with Russian origin (Table 14) (I) 30. Considering an approximate 
rate of 75% of viremic infection of all HCVAb-positive findings, Kurdish, 
Russian and Somali-origin migrants represent approximately one-tenth of 
CHC infections in Finland 60, 64, 223.  
Currently Finnish national guidelines do not address HCV testing among 
migrants. Finnish national HCV strategy suggests implementation of HCV 
screening among asylum seekers from high-prevalence countries 223. ECDC 
guidelines, on the other hand, support HCV testing among migrants from 
HCV-endemic areas (prevalence >2%) 36. The substantial burden of HCV 
observed among Russian origin migrants implies that in case HCV screening 
among migrants is to be adopted in Finland in the future, screening 
recommendations should consider strategies to reach labour migrants, 
students and migrant family members.  
6.2.3 HIV 
No cases of HIV infection were identified among Kurdish, Russian and 
Somali-origin migrants, which can be explained by the relatively low HIV 
prevalence in countries of origin and the number of individuals screened in 
the Maamu survey. According to UNAIDS estimates for 2017, the prevalence 
of HIV among adult population in Iran was 0.1%, in Somalia 0.1%, in Russia 
1.2% and 0.8% in Eastern Europe and Central Asia 133, 135. Also, selective 
migration of healthy individuals might play a role 6. 
Overall HIV seroprevalence among all asylum seekers was at low level 
(<1%, III), and comparable or lower than in previous studies among asylum 
seekers in Europe during the migrant crisis, when 0–4% HIV seroprevalence 
rates were observed 150, 158, 160, 324, 336, 339-341, 401, 403, 405, 406. Most of these 
studies included general asylum seeker populations 158, 160, 336, 339, 401, 405, 406 
and some were conducted in healthcare settings 324, 340, 341, 403. Previously, 
higher HIV prevalence has been observed among asylum seekers from SSA 
and Eastern Europe in comparison to other regions of origin 324, 339, 340. 
Evidence of cost-effectiveness of HIV testing among migrants in the 
EU/EEA is scarce 300, 407. ECDC has recommended HIV screening among 
migrants from areas with generalized epidemics (prevalence >1%) and 
among those at increased risk for exposure to HIV 36. Finland implements 
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the ECDC guideline among refugees and asylum seekers 272. Finnish national 
HIV strategy suggests expanding HIV screening also to migrant populations 
beyond refugees and asylum seekers 145. Results from this study support 
continuation of HIV screening among asylum seekers. For other migrant 
populations – such as for Russian-origin migrants – strategies to reach at-
risk migrants in Finland should be evaluated. 
6.2.4 SYPHILIS 
TrpaAb seropositivity affected especially Russian and Somali-origin 
migrants. TrpaAb seroprevalence was higher among Russian-origin migrants 
than among the Finnish general population (2.9 vs. 0.11% respectively). (I) 
Both Somali-origin migrants and asylum seekers appeared to have 
comparable or higher TrpaAb seroprevalence than the general population in 
Finland (I, III). TrpaAb seroprevalence among Kurdish-origin migrants was 
similar to the general population in Finland (I). 
According to WHO, the prevalence of positive syphilis serology in 
antenatal care was 0% in Iran (2017) and Iraq (2010), and 1.4% in Somalia 
(2017) 408. Rates are comparable to the ones observed in Maamu survey (I). 
For Russian origin migrants, the observed TrpaAb seroprevalence rates seem 
higher than observed in previous literature. However, no recent data on 
syphilis prevalence among the general population seems to be available. In a 
review by Kenyon et al. a syphilis prevalence of 0-0.5% in Russia during 
1990–1999 is presented mainly based on ANS data 148. The Global Burden of 
Diseases study modelled a syphilis prevalence in Russia 0.18% in 2012 98.  
TrpaAb seroprevalence rate among overall asylum seeker population was 
low (<1%, III), and comparable or lower than in previous publications among 
asylum seekers and refugees in Europe during the migrant crisis. Previous 
studies have observed 0.1–3.8% of asylum seekers to have positive syphilis 
serology 150, 160, 324, 339, 401, 405. The majority of the studies included general 
asylum seeker populations 160, 339, 401, 405 and one was conducted in a 
healthcare setting 324. 
TrpaAb seroprevalence increased with age among Russian and Somali-
origin migrant populations in the Maamu survey and among asylum seekers. 
Among Kurdish migrants, TrpaAb seroprevalence seemed to decrease with 
age. (Tables 12 and 13) (I, III) While interpreting the results, it’s important to 
keep in mind the limits of sparse data especially among Kurdish migrants. 
Increasing TrpaAb seroprevalence rates with age can be explained by 
prolonged time of exposure and accumulation of risk factors for 
transmission. Previously, increased age has been observed as a predictor of 
syphilis seropositivity among refugees 151. 
Syphilis notification incidence increased significantly in FSU countries 
with the dissolution of the Soviet Union in 1991 followed by a decrease in 
governmental healthcare investments, marginalization of especially women 
  
and emergence of HIV epidemic, and was reflected in Finland also 154, 409, 410. 
As we included migrants that had immigrated to Finland after 1995, the 
majority of Russian-origin participants in Maamu survey have lived in Russia 
during this syphilis epidemic. Contrasting to the observation of higher 
syphilis seroprevalence in the Maamu survey among Russian-origin women 
compared to men, notification rate of syphilis in Russia during 1985–1996 
showed no gender difference 410. (I) 
The burden of syphilis affected Russian-origin migrants especially, the 
largest migrant population in Finland (Table 14) (I). Current syphilis 
screening guidelines among asylum seekers and refugees cannot target this 
burden as the majority of migrants from Russia and the FSU have 
immigrated for employment, studies or for family reasons 272, 376. 
Furthermore, as TrpaAb seroprevalence was highest among persons over 30 
years of age, universal ANS might not address this burden. 
Syphilis was not considered as a key infectious disease among migrants in 
Europe by the ECDC ad hoc scientific panel and hence effectiveness and cost-
effectiveness of syphilis screening among migrants in EU/EEA was not 
systematically assessed 36. This study contributes for the evidence that some 
migrant populations are especially vulnerable to syphilis and that targeted 
screening strategies should be considered 280. 
6.3 IMPLEMENTATION OF SCREENING 
The results from publications I and III suggest that there are difficulties in 
implementing the national infectious disease screening guidelines 272. The 
overall screening coverage of hepatitis B and C, HIV and syphilis among 
eligible asylum seekers to Finland during 2015–2016 (60.6%, III) was lower 
than the self-reported coverage of infectious screening after arrival among 
resident Kurdish, Russian and Somali-origin migrants who had immigrated 
as refugees or asylum seekers after 1995 (87.5%, I). The lower coverage 
among asylum seekers can be explained partly by difficulties in scaling up the 
service provision during the large influx of asylum seekers in fall 2015, and 
by the emergence of regional austerity measures that restricted screening 
services 397, 411. 
Upon granting of asylum and residency in Finland, the responsibility for 
infectious disease screening is transferred from the immigration authorities 
to the municipalities. Most municipalities offer health examinations for 
newly arrived refugees and asylum seekers. Labour migrants are usually not 
targeted unless they are in need of integration and employment services. 269 
Labour migrants, students and family members with migrant origin are met 
unsystematically through occupational healthcare, student healthcare and 
ANS. During these health examinations, infectious disease screening is 
offered for those who haven’t been screened during the asylum process. This 
double-check can explain the better coverage among resident migrants 
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compared to asylum seekers. Nevertheless, poor screening coverage may 
allow the spread of infections among persons not linked to care and 
jeopardizes the cost-effectiveness of screening (Figure 2) 208, 280. 
Suboptimal infectious disease screening coverage among migrants was 
also observed in a recent systematic review, where the coverage ranged from 
14.5–92.5%, and 0.12–79.0% of migrants did not complete screening. Based 
on the findings, Seedat et al. conclude that while selective screening of 
infectious diseases seems to be acceptable among migrants, more emphasis 
needs to be put on engaging migrants in screening and linkage-to-care in 
order to improve screening effectiveness and cost-effectiveness. 
Furthermore, the evidence base for evaluating the operational effectiveness 
of infectious disease screening among migrant populations in EU/EEA needs 
to be strengthened. 208 In Finland, operational effectiveness of infectious 
disease screening among migrants is not systematically monitored 274. 
Previous HIV testing was reported by 13–53% of the resident Kurdish, 
Russian and Somali resident migrants and asylum seekers (I, III, IV), and by 
18% of young adult general population in Finland (IV). As observed, women 
tend to have higher HIV testing rates due to usage of SRH services 88, 207, 210. 
The lower rate of previous self-reported HIV testing among Kurdish migrants 
can be explained by the national guidelines that do not recommend HIV 
testing for asylum seekers and refugees originating from Iran and Iraq 311. 
However, the low rates of self-reported testing among migrants in general 
suggest that some might not acknowledge having participated in screening 
and that opportunities for pre-test counselling, health education and 
prevention have been missed.  
As opposed to previous studies, older age was not associated with higher 
HIV testing rates in the Maamu survey (I) 210. Borderline association of 
participation to previous HIV testing among those asylum seekers more 
knowledgeable on HIV implies that increased knowledge may increase HIV 
testing frequency, and this is supported by previous literature (IV) 207, 210. 
Interestingly, self-reported HIV testing rates among migrants were 
significantly lower than in a recent cross-sectional multicentre survey that 
applied convenience sampling in nine European countries, suggesting 
possible lower availability of testing for migrants in Finland compared to 
other EU countries 207. 
Several delays from immigration to screening and diagnosis were 
observed among resident migrants (I) and asylum seekers (III). Only one-
fifth of diagnoses in the Maamu survey had been diagnosed and notified 
within one year after immigration. The burden of missed diagnoses was 
largest among Russian migrants not targeted by the current national 
screening guidelines (Table 14) 226, 272. Furthermore, the substantial 
prevalence of missed hepatitis B diagnoses among Somali-origin migrants, 
the majority of whom had immigrated as refugees or asylum seekers and 
hence should have been offered screening upon arrival, suggests either 
suboptimal coverage of screening after arrival or low hepatitis B vaccination 
  
coverage resulting in infections post-migration (I). These results add to the 
evidence that migrants use primary health services frequently in particular, 
but opportunities for PITC and diagnosis are being missed 207, 209. 
The association of missed diagnoses and self-reported previous diagnosis 
of a blood-borne infection suggests that migrants might have been diagnosed 
previously in a country other than Finland (I). However, unless a diagnosis is 
confirmed in Finland, migrants are not likely to be followed-up for their 
infection. Among Somali-origin migrants, living in a permanent relationship 
protected from missed diagnosis, which could translate to safer sexual 
practices (I). Daily smoking, on the other hand, was associated with 
increased risk for missed diagnosis and could reflect health-seeking 
behaviours (I). 
Gender was not a significant predictor of missed diagnosis. The observed 
delays from immigration to diagnosis were longer than reported among HIV-
positive migrant women attending ANS in Finland, adding to the evidence of 
the benefits of universal screening in ANS 146. Similarly, in France, a study 
reported a median delay from immigration to CHB diagnosis of four years for 
men and two years for women, with more women being diagnosed through 
systematic screening such as ANS 321. Another study involving the same 
subjects concluded a delay from immigration to HIV testing of two years both 
among migrant men and women attending primary healthcare 216. 
Timing of screening for blood-borne and sexually transmitted diseases 
during a large influx of refugees has not been previously described. A study 
from Sweden approximated a delay of five months from immigration to 
referral for TB assessment 341. The observed longer delay to screening among 
adults as compared to children suggests that children as a vulnerable 
population were prioritized in health services (III).  
To summarize, the observations regarding the implementation of 
infectious disease screening in Finland imply that the coverage of the 
multiphasic screening according to national guidelines is suboptimal, there 
are delays from immigration to screening and diagnosis, and the uptake of 
HIV testing might be at lower level in comparison to other EU countries (I, 
III, IV). Hepatitis B vaccination coverage among VFR travellers and family 
members of CHB patients might be insufficient to prevent infections after 
immigration. Additionally, migrant populations other than refugees and 
asylum seekers are not reached by current screening recommendations. In 
order to increase the effectiveness and cost-effectiveness of screening among 
migrants, these issues should be addressed 208. 
The most beneficial screening strategies consider the heterogeneity of the 
migrant populations and the relative contributions of migrants to the overall 
epidemics of hepatitis B and C, HIV and syphilis 39, 40, 142. In order to reach all 
infected, most likely several parallel tailored strategies such as systematic 
and opportunistic screening and outreach services are needed. Potential 
approaches include exploiting and broadening existing approaches such as 
ANS to include fathers, extending screening after arrival to migrant 
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populations other than refugees and asylum seekers, applying multiphasic 
testing, and ensuring the coverage, uptake and continuum of care as well as 
reasonable prices of drugs alongside the screening trajectory (Figure 2) 41, 88, 
208, 223, 407. Previously, approaches for CHB and HCV screening among 
migrants have been summarized by the HEPscreen consortium 412. The 
national ANS working group has suggested evaluation of effectiveness of 
antenatal hepatitis C screening 88. 
6.4 HEALTH LITERACY 
Both young adult asylum seekers and the young adult general population in 
Finland had important gaps in HIV-related knowledge that might increase 
risk behaviour and delay testing and diagnosis. The gaps were especially 
pronounced among young asylum seekers. UNGASS composite score was 
below the international target of 95% for both populations 249. (IV) 
In 2005–2016 UNGASS reports, Algeria, Egypt, Eritrea, Finland, Iraq, 
Russia, Saudi-Arabia, Somalia and Syria did not report data on HIV KAP 
among young people. For 2016, data were available for Cameroon, Ethiopia, 
Gambia, Iran, Morocco and Nigeria, where 18.3–63.2% of young people aged 
15 to 24 years were knowledgeable about HIV, based on UNGASS composite 
score. 413 The reported rates from SSA countries support our observation that 
better HIV knowledge was associated with SSA origin among young asylum 
seekers to Finland (IV). Migrant regions of origin with generalized HIV 
epidemics, such as SSA, may explain previous exposure to preventive 
messages and better performance in knowledge assessment. 
In addition to region of origin, previous studies have consistently 
observed higher HIV and STI knowledge among migrants to be associated 
with higher educational status 251, 253-255, 257. Furthermore, previous studies 
have shown contradictory effects of age and gender with HIV knowledge 251, 
253, 255, 256. In the TIE survey, better knowledge was associated with higher 
education and female gender. However, the majority of young asylum seekers 
were male, less educated and had low levels of HIV-related knowledge 
compared to the general population making them vulnerable to HIV. (IV) 
SRH knowledge among secondary school, vocational school and high 
school students in Finland has decreased between 2008 and 2013 270. Both 
first and second-generation migrant-origin adolescents are known to have 
lower SRH knowledge in comparison to Finnish origin adolescents 414. Young 
girls have been consistently more knowledgeable than boys 270. Differences 
among migrant and Finnish-origin adolescents were explained by parents’ 
socio-economic background and by cultural differences in how SRH issues 
are discussed in families 414. 
Passive sources of HIV information were preferred by young adult asylum 
seekers as opposed to interpersonal strategies preferred by the general 
population young adults in our study (IV). Healthcare workers have an 
  
important role in HIV information delivery for young asylum seekers. 
Curriculum-based SRH education in schools is recognized as being 
influential both among young people and service providers 270. 
Acknowledging the preferred sources of HIV information might increase the 
acceptability of SRH education among adolescents and young adults with 
different migration backgrounds 280. 
6.5 SUMMARY OF FINDINGS 
 
Migrants represent a key population for the prevention and control of 
hepatitis B and C, HIV and syphilis epidemics in Finland. Migrants are 
vulnerable to infections pre- and post-migration and bear a disproportionate 
burden of disease. Data from current epidemiological surveillance are 
inadequate for the development of evidence-informed public health policies. 
This study describes the burden of infections among migrants of Kurdish, 
Russian and Somali origin and among asylum seekers in Finland, identifies 
gaps in prevention and suggests possible actions for public health response. 
Population-based surveys are suitable for evaluation of infectious disease 
prevalence and risk factors. Results from the study demonstrate that 
previous diagnosis of hepatitis B or C, HIV or syphilis did not influence 
participation in the migrant population-based survey (I). A high acceptability 
of provider-initiated opt-in multiphasic hepatitis B/C/HIV/syphilis 
screening was achieved through enhanced pre-test counselling. Screening 
offers were especially accepted by individuals with lower socio-economic 
status. (I, II) 
 Seroprevalence of hepatitis B and C, HIV and syphilis differed among the 
study populations but were in general lower or comparable with reports from 
countries of origin as well as among migrants and asylum seekers in other 
high-income, low-prevalence countries (I, III). Kurdish migrants had low 
levels of infections (I). Russian-origin adult migrants, the largest migrant 
population in Finland, had a substantial burden of hepatitis C and syphilis. 
Somali-origin migrants were especially vulnerable to hepatitis B. Screening 
of asylum seekers yielded low levels of hepatitis B, HIV and syphilis 
infections.  
Lower or comparable seroprevalence rates suggest selective migration of 
healthy individuals: the so-called healthy migrant phenomenon. Moreover, 
the observed low seroprevalence rates imply that access to care of hepatitis B 
and C, HIV or syphilis in Finland does not serve as a pull factor for 
migration. The results support the use of available in-country seroprevalence 
estimates in assessing the burden of hepatitis B and C, HIV and syphilis 
burden among other migrant populations. 
Screening coverage of the migrant populations included in this study was 
suboptimal, which might endanger the effectiveness of the screening 
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programme. Repeated health examinations during the asylum process and 
after receiving residency increase the screening coverage among resident 
migrants. The asylum process is as a window of opportunity for infectious 
disease prevention and early diagnosis. (I, III) 
Previous HIV testing was reported by fewer than a third of all migrants 
and general population young adults, despite these being key populations for 
STI prevention (I, IV). For chronic and often asymptomatic infections such 
as hepatitis B and C, HIV and syphilis, screening is the key for early 
diagnosis, treatment and success of secondary prevention. Both migrant and 
general population young adult women reported more testing, highlighting 
the success of opt-out provider-initiated universal screening in ANS and SRH 
service contexts. Men and fathers could also be reached through existing 
structures such as the ANS. 
 Current screening strategies have failed to diagnose more than half of the 
cases of hepatitis B and C and syphilis among resident Kurdish, Russian and 
Somali-origin adult migrants in Finland (I). Missed diagnoses imply missed 
opportunities for early diagnosis, treatment and prevention. Missed 
diagnoses increase morbidity among undiagnosed patients and have negative 
impacts also for society and communities, including higher healthcare costs 
related to late diagnosis and disease complications, and the risk of further 
transmission of infections.  The highest proportion of missed diagnoses was 
observed among Russian-origin migrants not targeted by the current 
screening guidelines. Missed hepatitis B diagnoses among Somali-origin 
migrants suggest low coverage of protective immunity and infections post-
migration. 
To assess the effectiveness of infectious disease screening among 
migrants, data on relevant background factors, time of immigration, number 
of persons eligible for screening, acceptability of screening, number and time 
of screenings performed, screening completion and yields is needed (Figure 
2). For asylum seekers, the centralized procurement of healthcare services 
provides a feasible option for data collection (III). However, multisectoral 
collaboration between public health professionals, immigration officials and 
private and public sector healthcare providers is necessary in order to 
transform the data to inform public health decision making. 
Health literacy is a prerequisite for healthy behaviours and practices such 
as participation in screening and vaccinations and condom use. Adolescents 
and young adults are recognized as a key population for prevention of blood-
borne and sexually transmitted infections in Finland. First-generation 
migrants might have not been exposed to health education in their countries 
of origin and might not be familiar with the use of the healthcare system and 
their entitlements to care in the CCOR. Results from this study demonstrate 
that young adult asylum seekers have important gaps in HIV-related 
knowledge in comparison to young adult general population, and that there 
are cultural differences in preferred sources of SRH information (IV). The 
  
kind, quality and effectiveness of civic information provided to resident 
immigrants and asylum seekers should evaluated in Finland. 
In addition to barriers to screening, migrants have been reported to have 
problems in accessing care and achieving optimal treatment outcomes. In 
order to ensure the continuum of care for migrants, these individual, social 
and structural barriers should be addressed. 
6.6 STRENGTHS AND LIMITATIONS OF THE STUDY 
This thesis is the first comprehensive assessment of the epidemiology of 
hepatitis B and C, HIV and syphilis among different migrant populations in 
Finland. Using a multimethod approach, the study examined the 
performance of different strategies for prevention and early diagnosis of 
infections among migrants. The study lays the groundwork for further 
research and policy development on infectious disease control among 
migrants in Finland.  
To increase the external validity of the results, the study included 
population-based samples of major resident migrant populations (I, II) and 
general young adult populations (IV) as well as a total population sample of 
all asylum seekers in Finland during 2015–2016 (III). Non-participation 
analysis revealed no difference in infectious disease notification prevalence 
among participants and non-participants in the Maamu survey (I). 
Nevertheless, a participation bias is likely to occur as survey participants 
might differ from non-participants with respect to characteristics that are not 
measured in the survey. The influence of participation bias is strongest in the 
TIE survey that applied convenience sampling (IV).  
Survey data also has response and recall biases (I, II, IV). Anonymity and 
computerized responses in TIE and WAD 2014 surveys respectively may have 
decreased the social desirability bias (IV). One-sixth of young adult asylum 
seekers in the TIE survey were unable to read well in their mother tongue 
and they might have needed interpretation to complete the questionnaire, 
which might have influenced the results.  
Population-based seroprevalence surveys are scarce and they provide 
valuable information on the prevalence of determinants for health in the 
general migrant populations 21, 140. Some information on migrant specific 
vulnerabilities to hepatitis B and C, HIV and syphilis was not collected in the 
Maamu and TIE surveys (MSM, sex work). Additionally, future assessments 
should also consider determinants of migrant health such as sexual mixing 
and imprisonment. Furthermore, associations of determinants for health and 
health outcomes observed in cross-sectional settings do not imply causation. 
This is especially relevant for studies aiming to evaluate the temporary 
relationship between migration and infection 21. 
Testing seropositive for HBsAg, HCVAb or TrpaAb was a rare event in the 
studied migrant populations reflected by the broad confidence intervals 
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around the point estimates especially after stratification (I). In order to 
establish the relationship between infection prevalence and various 
determinants for health, such as age, larger population samples are needed. 
For this purpose, national steering and organization of asylum seekers 
healthcare provides an opportunity 415. However, increasing the sample size 
does not necessarily remove the uncertainties related to sparse data. 
Our results demonstrate that surveys complement register data and can 
be used to describe the risk factors and burden of missed infections among 
general populations. Other sampling techniques, such as snowball 
recruitment, might be more beneficial in collecting information on specific 
risk groups, although they are not able to estimate the size of the total 
population 294.  
Infectious disease register data is limited to the population that has been 
tested, diagnosed and notified in the register. Quality of register information 
is influenced by the sensitivity, specificity, representability and accuracy of 
the data 5. Only cases that fulfil specific case definitions are included. 
Differences in register case criteria and incompleteness of information on 
immigrant backgrounds hamper attempts to compare infectious disease 
incidence among migrants between countries 4, 416.  
The NIDR case criteria for CHB, CHC, HIV and syphilis differ slightly 
from those adopted by the ECDC and the CDC 395, 396. The main difference in 
the surveillance case criteria is related to a lacking requirement for follow-up 
and control specimens in the NIDR, resulting in possible overestimation of 
the number of CHB, CHC, HIV and syphilis cases. On the other hand, 
considering hepatitis B and C, and syphilis diagnoses that reoccur within fifty 
years as single cases in the NIDR might underestimate the number of 
recurrent infections. 
Migration background in NIDR is derived from physicians’ notifications 
and through register linkage to PIS. Difficulties in merging notifications 
among temporary visitors, such as tourists, asylum seekers and migrants in 
irregular situations reported with temporary PICs into single cases might 
result in overestimation of the number of cases. Furthermore, prediction of 
the number of infected persons currently living in Finland based on NIDR is 
prone to overestimation since emigration information from the PIS is rarely 
available. Quality of NIDR with respect to migration parameters has not been 
evaluated. Previous studies also suggest possible misclassification of risk 
factors and routes of transmission among migrants 94. 
The procurement register data of asylum seekers health services did not 
allow for the stratification of seroprevalence rates in population sub-groups 
by country of origin or sex. The seroprevalence rates are likely to differ 
considerably between migrant population sub-groups. Also, the data for the 
numerator (number of screenings performed) and denominator (number of 
asylum applications registered) were derived from different sources. It is 
unlikely, but possible, that a small proportion of the screenings might have 
been procured from other service providers than the two national private 
  
providers supplying data for the study and thus the coverage estimates could 
be underestimates.  
Moreover, the data cannot differentiate between screening tests and test 
performed due to other indications. There were more HBsAg tests than 
TrpaAb tests performed among asylum seekers (22,144 and 22,016 tests 
respectively; Table 9), suggesting that 0.6% of HBsAg tests were performed 
due to an indication other than screening. Persons tested outside screening 
guidelines might differ from the rest of the population with respect to risk 
factors for infection. 
Migrant populations are heterogeneous. This study examined specific 
first-generation resident adult migrant populations and asylum seekers in 
Finland. Although Kurdish, Russian and Somali-origin migrants represent 
the third, first and fourth largest migrant populations in Finland, 
respectively, together they accounted for only one-third (33.2%) of the total 
number of first-generation migrants in Finland in 2017 30.  
Migrants from Estonia (second largest group), China (fifth) and Thailand 
(sixth) all have very specific risk profiles for blood-borne and sexually 
transmitted infections. Estonia has the second highest HIV notification 
incidence among EU/EEA countries and an adult HIV prevalence of 0.7% in 
2017 133, 136. HIV prevalence in Thailand is estimated at 1.1% 133. Migrants 
from South and South East contributed for 5.0% of the HIV cases among 
migrants and 1.9% of all cases during 2007–2011 in EU/EEA 4.  During 
2015–2016, 7–18% of residency permits in Finland were granted on the basis 
of refugee status 417-420. Hence, the results of the study cannot be generalized 
to all migrant populations in Finland. 
Limitations of HBsAg, HCVAb, HIVAgAb and TrpaAb seropositive 
findings should be kept in mind. HBsAg negative persons can be susceptible 
for infection, have resolved the infection spontaneously and developed 
natural immunity, or vaccinated. In order to understand the proportion of 
migrants who would benefit from hepatitis B vaccinations, an assessment of 
HBcAb and HBcAb seroprevalence rates should be conducted. 
HCVAb-positive persons should be tested for HCV-RNA in order to 
conclude CHC diagnosis. HCVAb-positive and HCV-RNA negative 
individuals should be counselled, and if presenting simultaneous risk factors 
for HBV, offered HBV vaccinations. A recent infection with HCV can test 
HCVAb negative.  
Establishing syphilis diagnosis among TrpaAb-positive individual 
requires further testing, patient history and clinical examination. 
Considering that treponemal tests for syphilis screening were commonly 
adopted in Finland only after 2005, some missed TrpaAb cases in the Maamu 
survey might have actually been screened before 2005 with non-treponemal 
tests 88. In fact, seven out of eleven TrpaAb-positive cases in the Maamu 
survey had immigrated before 2005. 
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7 CONCLUSIONS 
Based on observations from this study, the following conclusions may be 
drawn: 
 
1. Screening for hepatitis B and C, HIV and syphilis is feasible in migrant 
population-based health surveys and does not deter survey participation. 
High acceptability of multiphasic opt-in provider-initiated screening of 
hepatitis B and C, HIV and syphilis among migrants of Kurdish, Russian 
and Somali origin should encourage health professionals to actively offer 
screening. Appropriate pre-test counselling can further increase test 
acceptance. (publications I and II) 
 
2. Seroprevalence rates of hepatitis B and C, HIV and syphilis differ among 
different migrant populations and asylum seekers in Finland, but they 
seem to be lower or comparable to in-country populations and migrants 
in other high-income countries. Russian-origin migrants, the largest 
migrant population in Finland, carry a large burden of infections that is 
not addressed by the current selective screening among forced migrants. 
Moreover, hepatitis C screening among at-risk migrants is currently not 
included in the national screening guidelines despite of evidence 
supporting cost-effectiveness. To address this burden, strategies to 
expand after-arrival screening of hepatitis B, HIV and syphilis to all 
migrant populations at-risk and inclusion of hepatitis C screening should 
be adopted. (publications I and III) 
 
3. Missed hepatitis B and C and syphilis diagnoses among Kurdish, Russian 
and Somali-origin migrants, suboptimal coverage of screening among 
screening eligible asylum seekers and observed rates of previous HIV 
testing suggest barriers to services among different migrant populations 
in Finland. Coverage, as well as other elements contributing to screening 
effectiveness should be monitored, and gaps identified and addressed. 
For asylum seekers, gaining residency and entitlement to municipal 
health services provides an opportunity to increase screening coverage. 
Missed hepatitis B diagnoses among Somali-origin migrants suggest 
missed opportunities for vaccinations. Screening of hepatitis B should 
aim both at identifying infected individuals for follow-up and treatment 
and uninfected persons at-risk for hepatitis B, who would benefit from 
hepatitis B vaccinations. Missed diagnoses among Russian migrants and 
missed hepatitis C diagnoses in all investigated migrants demonstrate 
that current opportunistic screening approaches do not compensate for 
lacking screening programme. (publications I, III and IV) 
 
  
4. Gaps in HIV-related knowledge both among young adult asylum seekers 
and young adult general population might dispose these groups to risky 
behaviour and HIV. Approaches that are accepted by young people need 
to be designed and implemented. The asylum process is a window of 
opportunity for health promotion. (publication IV) 
7.1 SUGGESTIONS FOR FURTHER RESEARCH 
 
1. Recognizing migration as a global megatrend and acknowledging 
migrants’ vulnerabilities to blood-borne and sexually transmitted 
infections, migrant health and infectious diseases should be included on 
the public health research agenda. Public health institutes and 
universities should provide guidance for strategic research in migrant 
health and information needed for evidence-informed decision making. 
Non-academic organizations such as NGOs should be included as active 
partners in research and development. 
 
2. A comprehensive evaluation of time, location and population-specific 
epidemiology of the key blood-borne and sexually transmitted infections 
among migrants in Finland, including estimation of the proportion of 
post-migration infections, should be conducted. The evaluation should 
aim at identifying pockets of especially vulnerable migrants and provide 
suggestions to reach these populations. 
 
3. Surveillance of hepatitis B and C, HIV and syphilis among migrants 
should be strengthened with respect to the migration parameters in the 
NIDR and through linkage with the PIS in harmony with the European 
framework 416. Case criteria for infections should be harmonized with 
regional and global public health institutes and made publicly available 
for clinicians and researchers using NIDR. Quality of NIDR should be 
evaluated. 
 
4. Infectious diseases assessments should be included in future population-
based surveys, and resources for screening should be ensured. Future 
surveys should attempt to include migrants from various countries of 
origin and also from the second generation. Prospective register studies 
based on the population-based surveys could provide more information 
on the risk factors for infections. 
 
5. VFR and other travel among migrant populations should be described 
and infectious disease risks among travel assessed. 
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6. An assessment of HBsAg, HBcAb and HBsAb seroprevalences among key 
migrant populations should be conducted to evaluate the coverage of 
targeted hepatitis B vaccination strategy. 
 
7. Different strategies and best practices in reaching and providing civic 
information and SRH education for different migrant populations in 
Finland should be mapped and evaluated for effectiveness using mixed 
methods approaches. 
7.2 OPPORTUNITIES FOR PUBLIC HEALTH RESPONSE 
 
1. Acknowledging the current trends in migration and epidemiology of 
hepatitis B and C, HIV and syphilis in Finland, a coordinated public 
health response should be implemented based on previous experience 154, 
333, 421. 
 
2. Healthcare providers should acknowledge the high acceptability of 
provider-initiated multiphasic screening for blood-borne and sexually 
transmitted infectious diseases. Approaches to facilitate screening offers 
among healthcare staff should be adopted, including training, multiphasic 
laboratory referrals, and assisted decision making. Health providers 
should acknowledge that infectious disease risk-assessment should be 
based on a comprehensive evaluation of risks at individual level and take 
into consideration the determinants for health along the migration cycle 
(Figure 1). 
 
3. Acknowledging the international consensus on public health benefits of 
HBV, HCV and HIV screening among migrants and burden of syphilis 
among specific migrant populations in Finland, opportunities to expand 
current after-arrival screening to other at-risk migrant populations 
besides refugees and asylum seekers should be evaluated. Exploiting 
existing screening strategies, such as the ANS, could be beneficial.  
 
4. Taking into account the recent advances in HCV treatment, the cost-
effectiveness of expanding hepatitis C screening to refugees and asylum 
seekers in Finland should be evaluated. Existing organization of initial 
health services among refugees and asylum seekers and adopted 
multiphasic provider-initiated opt-out screening of CHB/HIV/syphilis 
could facilitate the introduction of HCV screening. 
 
5. Acknowledging the substantial proportion of missed hepatitis B infections 
among Somali-origin migrants, the cost-effectiveness of expanding 
hepatitis B vaccinations to all HBsAg negative first and second-generation 
  
migrants originating from countries with high CHB prevalence (>5%) 
among the general population as well as benefits of screening for 
protective immunity in conjunction with HBsAg should be evaluated. 
 
6. Systems and tools to monitor infectious disease screening effectiveness 
among migrants should be developed and adopted in collaboration with 
other stakeholders such as immigration officials, municipalities, regional 
governments, and private healthcare service providers. Monitoring data 
can be used to close gaps in implementation of screening. 
 
7. Barriers to opportunistic self-initiated screening for blood-borne and 
sexually transmitted infections should be lowered by ensuring the 
availability of free and anonymous screening within the public healthcare 
system, providing sustainable funding for low-threshold services, 
enabling community testing by non-medical staff, as well as self-sampling 
and self-testing. 
 
8. Health education concerning blood-borne and sexually transmitted 
infections among young people should be strengthened in coordinated 
collaboration among teachers of primary and secondary level schools, 
parents, NGOs and public healthcare. Asylum-seeking young people can 
be reached also through reception centres. Appropriate and youth-
friendly methods of delivering the health messages should be used. 
 
9. A continuum for care from prevention to diagnosis and treatment of 
hepatitis B and C, HIV and syphilis should be ensured for all migrants 
irrespective of immigration status. 
 
10. The public health response to hepatitis B and C, HIV and syphilis 
epidemics among migrants should acknowledge existing discriminatory 
structures and practices, racism and stigma, and strategies to eliminate 
these should be adopted. Migrants do not pose infectious disease threats 
to society but are themselves vulnerable to infections. Migrants should be 
involved in the development process. 
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Figure 3, p. 67: Flow chart on participation in hepatitis B and C, HIV and 
syphilis screening, and register linkage in the Maamu survey. 
 
Figure 4, p. 68: Flow chart on participation in HIV screening during Maamu 
survey and pilot survey in Helsinki. 
 
Figure 5, p. 74: Timing of the diagnosis in relation to arrival; %. Numbers 
inside columns represent number of cases. 
 
Figure 6, p. 75: Numbers of arrived of asylum-seeking adults and children 
from blood-screening eligible countries, and number of TrpaAb screenings 
performed for adults and children by month in 2015–2016. 
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